“à‰ÈŠw‘æ‚QuÀ
i˜_•¶”­•\j Akishita M, Horiuchi M, Yamada H, Zhang L, Shirakami G, Tamura K, Ouchi Y, Dzau VJ: Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics, 2: 13-20, 2000. Cui T, Nakagami H, Iwai M, Takeda Y, Shiuchi T, Tamura K, Daviet L, Horiuchi M: ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth. Biochem Biophys Res Commun, 279: 938-941, 2000. Funck CP, Adamec R, Lurje L, Capucci A, Ritter P, Shekan D, Slegers LC, Tavernier R, Ishikawa T: Atrial overdriving is beneficial in patients with atrial arrhythmias: First results of PROVE study. PACE, 23: 1891-1893, 2000. Hibi K, Takagi A, Zhang X, Teo TJ, et al.: Feasibility of a novel blood noise reduction algorithm to enhance reproducibility of ultra-high-frequency intravascular ultrasound images. Circulation, 102: 1657-63, 2000. Horiuchi M, Hayashida W, Akishita M, Yamada S, Lehtonen JY, Tamura K, Daviet L, Chen YE, Hamai M, Cui TX, Iwai M, Minokoshi Y: Interferon-gamma induces ATi2jreceptor expression in fibroblasts by Jak/STAT pathway and interferon regulatory factor-1. Circ Res, 86: 233-240, 2000. Ishikawa T, Sumita S, Kimura K, Kikuchi M, Kosuge M, Endo T, Sugano T, Shigemasa T, Usui T, Umemura S: Sinus node recovery time assessment by the overdrive suppression test employing an intravenous injection of disopyramide phosphate. Europace, 2: 54-59, 2000. Ishikawa T, Sumita S, Kikuchi M, Nakagawa T, Kosuge M, Kuji N, Kimura K, Tochikubo O, Usui T, Umemura S: Incidence of atrial flutter and fibrillation in patients with implanted physiological pacemakers. Jpn Circ J, 64: 505-509, 2000. Ishikawa T, Sumita S, Kimura K, Kikuchi M, Kosuge M, Nakagawa T, Matsushita K, Usui T, Umemura S: Efficacy of atrioventricular sequential pacing and diastolic mitral regurgitation in patients with intrinsic atrioventricular conduction. J Circ J, 64: 579-582, 2000. Ishikawa T, Sumita S, Nakagawa T, Ogawa H, Hanada K, Kobayashi I, Kosuge M, Shigemasa T, Endo T, Kimura K, Usui T, Umemura S: Long-term follow-up in patients with intra-Hisian atrioventricular block. J Artif Organs, 3: 149-153, 2000. Ito D, Ogasawara K, Matsushita K, Morohashi T, Namba K, Matsuki N, Kitaichi N, Inuyama Y, Hosokawa M, Nakayama E, Iwabuchi K, OnoEK: Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies. Immuno-biology, 201: 527-540, 2000. Kosuge M, Kimura K, Ishikawa T, Endo T, Shigemasa T, Okuda J, Sugiyama M, Tochikubo O, Umemura S: Relation between C-reactive protein levels on admission and pattern of acute myocardial infarction onset. Am J Cardiol, 86: 83-86, 2000. Kuji T, Kitamura H, Yasuda G, Umemura S, Kimura T, Shimizu S, Ikeda Y: Different pathological findings in each of four parathyroid glands in a long-standing hemodialysis. Clinical Nephrology, 54: 413-417, 2000. Matsushita K, Sugimoto T, Tagawa H, Iwamoto T, Oike Y, Kimura N, Ogura A: Potential factors regulating serum parathyroid hormone in maintenance hemodialysis patients: 4-year retrospective study. Clin Exp Nephrol, 4: 137-143, 2000. Matsushita K, Sugimoto K, Tsuruoka S, Fujimura A: Effect of fluvastatin on the renal function in five-sixth nephrectomized rats. Nephron, 86: 398-399, 2000. Miyajima E, Shigemasa T, Endo T, Hishiki S, Kawano Y: Guanabenz combination therapy inhibit sympathetic nerve activity and regresses left ventriculat hypertrophy. Cariovasc Drug Ther, 14: 61-66, 2000. Morohashi T, Ogasawara K, Kitaichi N, Iwabuchi K, OnoEK: Abrogation of negative selection by GVHR induced minor histocompatibility antigens or H-2D antigen alone. Immunobiology, 202: 268-279, 2000. Morohashi T, Ogasawara K, Kitaichi N, Iwabuchi K, OnoEK: Significant MLR but not CTL responses against recipient antigens generated in T cells from bone marrow chimeras recovered from acute GVHD. Bone Marrow Transplant, 26: 1069-1076, 2000. Namba K, Ogasawara K, Kitaichi N, Morohashi T, Sasamoto Y, Kotake S, Matsuda H, Iwabuchi K, Iwabuchi C, Ohno S, Ono_ K: Amelioration of experimental autoimmune uveoretinitis by pretreatment with a pathogenic peptide in liposome and anti-CD40 ligand monoclonal antibody. J Immunol, 165: 2962-2969, 2000. Nyui N, Yamanaka O, Nakayama R, Sawano M, Kawai S: Tako-Tsubo transient ventricular dysfunction. a case report. Jpn Circ J, 64: 715-719, 2000. Petrie JR, Morris AD, Ueda S, Small M, Elliott HL, Connell JMC: Trandrapril dose not improve insulin sensitivity in hypertensive patients with type 2 diabetes: Double blind, placebo-controlled, cross-over study. J Clin Endocrinol Metabol, 85: 1882-1889, 2000. Shigemasa T, Tochikubo O, Miyajima E, Kimura K, Ishikawa T, Endo T, Kobayashi I, Kosuge M, Hanada K, Umemura S, Mizushima S: The clinical significance of base heart rate during nighttime. Ther Res, 21: 1002-1007, 2000. Shionoiri H, Kosaka T, Kita E, Takizawa T, Takasaki I: Comparison of long-term therapeutic effect of an ACE inhibitor, temocapril, with that of a diuretic on microalbuminuria in non-diabetic essential hypertension. Hypertens Res, 23: 593-600, 2000. Sugimoto K, Ohmori M, Tsuruoka S, Harada K, Matsushita K, Kawaguchi A, Toh H, Fujimura A: Influence of dosing time of enalapril on the daily variation of pulmonary function: a preliminary study. Jpn J Clin Pharmacol Ther, 31: 701-704, 2000. Tamura K, Chen YE, Chen Q, Nyui N, Horiuchi M, Takasaki I, Tamura N, Pratt RE, Dzau VJ, Umemura S: Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor. iSpecial Issue: Control of Gene Expression by Catechola-mines and the Renin-Angiotensin System; Edited by Heinz Rupp, Ph.D. and Bernhard Maisch, M.D.jMol Cell Biochem, 212: 203-209, 2000. Tamura K, Chen YE, Lopez-Ilasaca M, Daviet L, Tamura N, Ishigami T, Akishita M, Takasaki I, Tokita Y, Pratt RE, Horiuchi M, Dzau VJ, Umemura S: Molecular mechanism of fibronectin gene activation by cyclic stretch in vascular smooth muscle cells. J Biol Chem, 275: 34619-34627, 2000. Tamura K, Chen YE, Horiuchi M, Chen Q, Daviet L, Yang Z, Lopez-Ilasaca M, Mu H, Pratt RE, Dzau VJ: LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression. Proc Natl Acad Sci USA, 97: 8513-8518, 2000. Ueda S, Masumori-Maemoto S, Ashino K, Nagahara T, Gotoh E, Umemura S, Ishii M: Angiotensin-i1-7jattenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man Hypertension, 35: 998-1001, 2000. Ueda S, Maemoto S, Umemura S: Response to Letter to the editor regardinggAngiotensin-i1-7jattenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in manhDHypertension 35ionline Letter to the editorjC2000. Uchino K, Fukuoka M, kawasaki N,Nakamaru M, Ochiai H, Kimura K, Umemura S: Acute eosinophilic myocarditis in a young woman. Jpn Circ J, 64: 711-714, 2000. Takeshita Y, Takagi N, Yamada A, Aikawa T, Umemura S: Diabetes Mellitius Associated with Rapidly Progressive Glomerulonephritis with Perinuclear Antineutrophil Cytoplasm Antibodies. Internal Medicine, 39: 154-156, 2000. Yoshida K, Ishigami T, Nakazawa I, Ohno A, Tamura K, Fukuoka M, Mizushima S, Umemura S: Association of essential hypertension in elderly Japanese with I/D polymorphism of the angiotensin-converting enzymeiACEjgene. J Hum Genet, 45: 294-298, 2000. A“c^ˆê˜YC‘O–{’qŽqC˜a“c@“ÄC”~‘º@•qFƒAƒWƒAƒIƒeƒ“ƒVƒ“i1-7j‚ÍŒ’í’j«‘O˜r’ïRŒŒŠÇ‚É‚¨‚¢‚ăuƒ‰ƒWƒLƒjƒ“‚ÌŒŒŠÇŠg’£ì—p‚ð‘‹­‚·‚éDTher Res 21: 1033-1036iProceedingC‘æ‚T‰ñt‚Æ‚ŒŒˆ³Œ¤‹†‰ïjC2000D ¬ì‰pKCÎì—˜”VCZ“cWˆêC¬—Ñ@òC›–ìW–õCd­’©•FC‰Ž“n@—ÍC–Ø‘ºˆê—YC”~‘º@•qFƒVƒ“ƒOƒ‹ƒŠ[ƒhVDDƒy[ƒXƒ[ƒJA‚¦ž‚ÝŠ³ŽÒ‚ÌS“àP”gƒAƒ“ƒvƒŠƒ`ƒ…[ƒhEƒqƒXƒgƒOƒ‰ƒ€‚ÌŒŸ“¢DlH‘ŸŠíC29: 394-397, 2000. ¬ì‰pKCÎì—˜”VCZ“cWˆêC¬—Ñ@òC›–ìW–õCd­’©•FC‰Ž“n@—ÍC–Ø‘ºˆê—YC”~‘º@•qFƒVƒ“ƒOƒ‹ƒŠ[ƒhVDDƒy[ƒXƒ[ƒJ[A‚¦ž‚ÝŠ³ŽÒ‚ÌS“àP”gƒAƒ“ƒyƒŠƒ`ƒ…[ƒhEƒqƒXƒgƒOƒ‰ƒ€‚ÌŒŸ“¢DlH‘ŸŠíC29: 394-397, 2000. Š¿“߉ë•FC–Ø‘ºˆê—YC¬›‰ë”üC“¡“cF”VC–{‹½—mˆê˜YCŽ“c‘×sCŠâ‘ò—S“ñC‹g“cŒ\ŽqC‰Ž“n@—ÍCÎì—˜”VC“È‹v•ÛCC”~‘º@•qFƒ_ƒCƒŒƒNƒgPTCA‹y‚уXƒeƒ“ƒg—¯’u‘OŒã‚Ì•ÂÇ‹ßˆÊ‘ÎÆŠ¥“®–¬Œa‚̕ω»DJpn J Interv Cardiol, 15:124-128, 2000. ¬ˆäŽè—TˆêCìŒû’|’jC•Ÿˆä˜aŽ÷C‹g“c@“OC‘å–ìˆÀŽÀC“c’†‰p•äCˆÀ–쌛ˆêC’·’JìÍ—YC”~‘º@•qF–¢”j—ô‚Å”­Œ©‚³‚ꂽƒoƒ‹ƒTƒ‹ƒo“´“®–¬áŽ‚Ì‚PŽèp—áDS‘ŸC32: 902-906, 2000. ‰–”V“ü—mCA“c^ˆê˜YC“ìàVN‰îC‚è@òFACE‘jŠQ–òƒyƒŠƒ“ƒhƒvƒŠƒ‹‚Ì–{‘Ô«‚ŒŒˆ³Š³ŽÒ‚É‚¨‚¯‚é”÷—ʃAƒ‹ƒuƒ~ƒ“”A—}§Œø‰Ê‚ÌŒŸ“¢D—Õ°–ò—C31: 43-44, 2000. d­’©•FC‹{“‡‰hŽ¡CàV“c—æ–¯C›–ìW–õC‰Ž“n@—ÍC¬›‰ë”üCž\‹v•ÛCCΈäác’jFŒŒŠÇŠg’£–ò‚Ì–«S•s‘SгŽÒ‚ÌŽ©—¥_ŒoŠˆ“®‚ւ̉e‹¿DTher Res, 21: 188-192, 2000. Žu˜a’‰ŽuC•H–Ø@’qC–q—R”üŽqC‰¡ŽR’mŽqC‚‹´—R—˜ŽqC–쑺³ªF“úíf—Âɂ¨‚¯‚邃RƒŒƒXƒeƒ[ƒ‹ŒŒÇгŽÒ‚ɑ΂·‚éHMG-CoAŠÒŒ³y‘f‘jŠQ܃ZƒŠƒoƒXƒ^ƒ`ƒ“‚Ì—L—p«‚ÌŒŸ“¢D–ò—‚ÆŽ¡—ÃC28: 701-706, 2000. Žu˜a’‰ŽuFEˆæˆÝŠàŒŸf‚Æ‚µ‚ẴyƒvƒVƒmƒQƒ“–@‚Ì—L—p«‚ÆŒoÏŒø—¦D‘æ‚T‰ñˆÝ޾г•a‘Ô¶—Œ¤‹†‰ïƒvƒŒƒiƒŠ[ƒZƒbƒVƒ‡ƒ“‹L˜^WC10-12, 2000. ‘ê‘ò—˜ˆêC–î‰Ô^’mŽqC•½˜aLmC–ØŒ´@ŽÀCŒË’J‹`KC‚–ØM‰ÃCˆÀ“c@Œ³C”~‘º@•qCˆîŽR‰Ã–¾C’†’Js—YC–k‘º@‹ÏF‰¡•lŽs—§‘åŠwˆãŠw•”‘æ“ñ“à‰È‚É‚¨‚¯‚ét¶ŒŸ•ñD‰¡•lˆãŠwC51: 187-191, 2000. ’†ŽR—ˆê˜YCŽR’†@CC‘ò–ì^lC“ûˆäL•vC’†“‡‰ëlCâ“c—TŽqC˜a“c@“ÄC“ìàVN‰îCŽRãLˆê˜YC‰Á”[’B“ñF4.2F SonesŒ^ƒJƒe[ƒeƒ‹‚É‚æ‚éŒožôœ“®–¬Š¥“®–¬‘¢‰e‚ÌŽŽ‚ÝDSŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“C15: 230-235, 2000. “ûˆäL•vC’†ŽR—ˆê˜YCŽR’†@CCàV–ìáÁlC‰Í‡Ë—YF‚½‚±‚‚ڗlS‹ØáŠQ‚ðŽ¦‚µ‚½‚¤‚ÁŒŒ«S•s‘S‚Ì‚P—áDJpn Circ J 64 Suppl.: 740 —Ñ@CˆêC‰“ŽRTˆêC’†”ö³sC–¼‘q•qOCX@—TsCª–{³‘¥C”~‘º@•qFPalmaz-SchatzƒXƒeƒ“ƒg—¯’uŒã‚É‚¨‚¯‚錌ŠÇŠg’£—lŽ®‚ÌŒŸ“¢DSŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“C15: 209-213, 2000. ˜a“c@“ÄCŽR’†@CCŽRãLˆê˜YC—Ñ@Ž®C’†ŽR—ˆê˜YC‰Á”[’B“ñFŠ¥“®–¬Ž¾Š³Ó”C•a•Ï•”‚É‚¨‚¯‚éΊD‰»‚̈Ӌ`DJ Cardiol, 35: 27-32, 2000. i1998”N•âˆâj “c‘ºŒ÷ˆêC”~‘º@•qC“ûˆäL•vC‚è@òCΈäác’jFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀ‚É‚æ‚錌ŠÇ•½ŠŠ‹Ø×–EƒtƒBƒuƒƒlƒNƒ`ƒ“ˆâ“`Žq”­Œ»’²ß‚Ì•ªŽqƒƒJƒjƒYƒ€‚ɂ‚¢‚Ă̌Ÿ“¢D–¬ŠÇŠwC38: 377-382, 1998 “c‘ºŒ÷ˆêFSŒŒŠÇŒn‘gD‚É‚¨‚¯‚郌ƒjƒ“-ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œnˆâ“`Žq‚¨‚æ‚Ñ×–EŠOƒ}ƒgƒŠƒbƒNƒXˆâ“`Žq‚Ì”­Œ»’²ß‹@\‚ɂ‚¢‚Ă̕ªŽq¶•¨Šw“IŒŸ“¢D㌴‹L”O¶–½‰ÈŠwà’cŒ¤‹†•ñWC12: 109-111, 1998
i‘@@àj Îì—˜”VFS•s‘S‚ɑ΂·‚邨[ƒVƒ“ƒOŽ¡—Â̌»ó‚Æ“W–]DW’†Ž¡—ÃC12: 549-554, 2000. Îã—FÍC”~‘º@•qF’Pˆêˆâ“`Žq‚ªŒ´ˆö‚Æl‚¦‚ç‚ê‚邌Œˆ³D“ú–{—Õà¬C58: 649-654, 2000. Îã—FÍC”~‘º@•qF’Pˆêˆâ“`Žq•ψقɂæ‚邌Œˆ³DzŠÂŠí‰ÈC48: 2082-2089, 2000. Îã—FÍC”~‘º@•qF‚ŒŒˆ³‚Ì“Œ—mˆãŠw“IŽ¡—ÃD“ÁW|‚ŒŒˆ³ÇŽ¡—ÂÌV‚½‚ȃXƒgƒ‰ƒeƒW[@Ž¡—ÃC82: 1367-1372, 2000. A“c^ˆê˜YC”~‘º@•qF–{‘Ô«‚ŒŒˆ³‚Ì‘å‹K–͉î“üŽŽŒ±D‘އ—Õà¬C49: 59-67, 2000. A“c^ˆê˜YC”~‘º@•qF––½zŠÂ“®‘Ô@‚ŒŒˆ³C“ú–{—Õ°C58: 340-344, 2000D A“c^ˆê˜YC”~‘º@•qF–{‘Ô«‚ŒŒˆ³‚Ì‘å‹K–͉î“üŽŽŒ±C‘‡—Õ°C49: 59-67, 2000D ‰Pˆä@FCX“c—L‹IŽqF޾•a‚Æ—Õ°ŒŸ¸@ƒNƒbƒVƒ“ƒOÇŒóŒQDŒŽŠ§ƒƒf¨ƒJƒ‹ƒNƒ‰[ƒNC52: 30-33, 2000. “à–ì˜aŒ°C”~‘º@•qF‡•¹Ç‚Ì‚ ‚邎‰ŒŒÇ‚ÌŽ¡—Ã@‚ŒŒˆ³Ç‡•¹Žž‚ÌŽ¡—ÃD“ÁW|‚މŒŒÇŽ¡—ÂÌV‚½‚ȃXƒgƒ‰ƒeƒW[DŽ¡—ÃC82: 1593-1597, 2000. ”~‘º@•qFŠª“ªŒ¾@‹ß ‚̘b‘è‚æ‚è@_“àˆãƒjƒ…[ƒX44†_“Þ쌧“à‰ÈˆãŠw‰ï ”~‘º@•qFˆ««‚ŒŒˆ³Ç‚ð—\–h‚·‚邽‚ß‚É@–ˆ“úƒ‰ƒCƒtC31: 51-53, 2000. ”~‘º@•qF–ò•¨—Ö@@—˜”A–òDÅVî•ñ‚ŒŒˆ³‚Ì‚·‚ׂÄ`‡•¹Ç‚ð‹N‚±‚³‚È‚¢‚½‚ß‚É`•ÊûNHK¡“ú‚ÌŒ’NC78-81, 2000. ”~‘º@•qF‚ŒŒˆ³Ž¡—ẪXƒgƒ‰ƒeƒW[@¡ŒŽ‚ÌŽ‹“_DŽ¡—ÃC82: 1278, 2000. ”~‘º@•qFŠª“ªŒ¾@‚ŒŒˆ³‚ð‚ß‚®‚éŋ߂̘b‘èDMedical View Point, 21: 1, 2000. ”~‘º@•qF‚Ç‚±‚܂ʼnð‚Á‚½‚Ì‚©|¶ŠˆKе•a‚̈â“`Žq|Œ’N‚©‚È‚ª‚íC391: 1, 2000. ŠC˜V–¼r–¾C“à–ì˜aŒ°C”~‘º@•qF~ˆ³–òŽ¡—Ã|‚È‚ºŒø‚­‚©|@aEb ŽÕ’f–òD¡“ú‚Ì‚ŒŒˆ³Ž¡—ÃC4: 24-25, 2000. ¬–ì]˜a‘¥C”‹´‘åŽ÷FƒLƒ‰[T×–EŠˆ«‰»‚É‚¨‚¯‚霑—R—ˆRŒ´’ñަזE‚Ì–ðŠ„iCross-presentationjD—Õ°–ƉuC33: 384-388, 2000. ì–¼ˆê˜NC‹g]_ˆê˜YC•x“c®•FCŽç’Jº•FC“¡“c—SŽŸC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñ¹Á‰»«’×á‡oŒŒ‚ÉŽ_•ª”å—}§Ü‚Í—LŒøHDŽ¡—ÃC82: 371-378, 2000D ì–¼ˆê˜NC‹g]_ˆê˜YC•x“c®•FCŽç’Jº•FC“¡“c—SŽŸC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñº’×á‡oŒŒ‚ɑ΂·‚é“àŽ‹‹¾Ž¡—ÃCŽèp‚Í‚à‚¤•K—v‚È‚¢‚©HDŽ¡—ÃC82: 1211-1218, 2000D ì–¼ˆê˜NCŽç’Jº•FC‹g]_ˆê˜YC“¡“c—SŽŸC•x“c®•FC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñ¿ŠÌ‘Ÿ•a‚É‚’`”’E‚ƒJƒƒŠ[H‚Í•K—v‚©HDŽ¡—ÃC82: 2439-2445, 2000D ì–¼ˆê˜NCŽç’Jº•FC‹g]_ˆê˜YC“¡“c—SŽŸC•x“c®•FC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñÁ–ìØÛŽæ‚ő咰ƒ|ƒŠ[ƒv‚Í—\–h‚Å‚«‚é‚Ì‚©HDŽ¡—ÃC82: 2809-2814, 2000D –ØŒ´@ŽÀC”~‘º@•qFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀŽó—e‘ÌhR–ò‚ÆACE‘jŠQ–ò‚ÌŽg‚¢•ª‚¯D“ÁW‚ŒŒˆ³|VŠî€‚ÆŽ¡—ÃŽwj|‘‡—Õà¬C49: 513-519, 2000. –ØŒ´@ŽÀC”~‘º@•qFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“ƒ^ƒCƒv1aŽó—e‘̈â“`ŽqŒ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚ét•a•ÏD—Õ°‚Ì‚ ‚ä‚ÝC45: 30-33, 2000. ‹vŽœ’‰ŽiC”~‘º@•qFŒŒˆ³‚Ì“ú“à•Ï“®‚ðl—¶‚µ‚½~ˆ³–ò‚ÌŽg‚¢•ûD‘‡—Õà¬C49: 951-952, 2000. ¬—Ñ@òCÎã—FÍC”~‘º@•qFƒCƒ“ƒXƒŠƒ“’ïR«‚ƃJƒeƒRƒ‰ƒ~ƒ“^ƒÀ|Žó—e‘Ì‹@”\D“ú–{—Õ°C58: 333-337, 2000D Ö“¡ŽŸ˜YCŽu˜a’‰ŽuC¼“c—æŒ\C¼ŠÛ@´C‹´–{³•qCò’J@–¾C•x“c®•FCç—t‰pŽqCì–¼ˆê˜NC‹{–{ˆêsC”~‘º@•qC‰F‚’¼ŽqFŒJ‚è•Ô‚·‰E‹G˜]•”’É‚ð‚Æ‚à‚È‚Á‚½‘ŠúŠÌ”~“Å‚Ì1—áD“úÁŽC97: 455-459, 2000. ‰–”V“ü—mC“ìàVN‰îC‰–”V“ü‘¾C•½˜aLmC‚è@òF‚ŒŒˆ³f’f‚ÆŽ¡—ÃVƒŠ[ƒY36‚”AŽ_ŒŒÇi’É•—j‚𔺂¤‚ŒŒˆ³‚ÌŽ¡—ÃD‰¡•lˆãŠwC51: 59-61, 2000. ‰–”V“ü—mC“ìàVN‰îC‰–”V“ü‰·C‰–”V“ü‘¾C•½˜aLmC‚è@òF‚ŒŒˆ³f’f‚ÆŽ¡—ÃVƒŠ[ƒY37‚ŒŒˆ³Ž¡—Ñæˆê‘I‘ð–ò‚Ì“Á«‚Ƈ•¹Ç‚Ì‚ ‚邌Œˆ³‚ɑ΂·‚é~ˆ³–ò‚Ì‘I‘ðD‰¡•lˆãŠwC51: 63-74, 2000. ‰–”V“ü—mF–ò•¨—Ö@|~ˆ³–ò‚Ì‘I‘ðDˆãŠw‚Æ–òŠwC43: 23-34, 2000. ‰–”V“ü—mFtáŠQ‚ð—L‚·‚邌Œˆ³‚Ì¶Šˆ—Ö@D–ˆ“úƒ‰ƒCƒtC31: 64-69, 2000. ‰–”V“ü—mC•½˜aLmC‚è@òFV‚µ‚¢~ˆ³–ò‚ÌŽ¡—ÃŒø‰ÊDt‚Æ“§ÍC48: 829-842, 2000. ‰–”V“ü—mC‚è@òFtd‰»Çi—Ç«td‰»ÇEˆ««td‰»ÇjD—Õ°ˆãC26: 1173-1178, 2000. ‰–”V“ü—mF‚ ‚Æ‚ª‚«Dt‚Æ“§ÍC49: 308, 2000. ‰–”V“ü—mC‘ê‘ò—˜ˆêC‚è@òFt‚Æ‚ŒŒˆ³|Ž¡—ÂÌi•àDt‚Æ“§ÍC49: 979-994, 2000. ™ŽR@vC´…@½Fd“xŠO‚ɑ΂·‚ézŠÂŠÇ—|ŠO«ƒVƒ‡ƒbƒN‚Æfluid resuscitation|W’†Ž¡—ÃC12: 1269-1277, 2000. ‚è@òC‰–”V“ü—mF’·Šú“§Í‡•¹ÇA‹ô”­Ç‚Ì•a‘Ô‚ÆŽ¡—ÃCŒŒˆ³ˆÙíC‚ŒŒˆ³Dt‚Æ“§ÍC49: 560-562, 2000. ‰–”V“ü—mC“¡“cF”VC‘ê‘ò—˜ˆêC‚è@òF’·Šú“§Í‡•¹ÇC‹ô”­Ç‚Ì•a‘Ô‚ÆŽ¡—ÃCŒŒˆ³ˆÙíC’ጌˆ³i–«E“§ÍŠújDt‚Æ“§ÍC49: 563-570, 2000. ‚è@òC”~‘º@•qF‚ŒŒˆ³‚Æ“®–¬d‰»C“®–¬d‰»”­Ç‚Ì‹@˜CƒŒƒjƒ“EƒAƒ“ƒWƒIƒeƒ“ƒVƒ“ŒnDzŠÂC21: 2-7, 2000. “c‘º@”ŽCì–¼ˆê˜NC‹g]_ˆê˜YCŽç’Jº•FC“¡“c—SŽŸC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñˆÝH“¹Ã–¬Šà‚ÌoŒŒ—\–h‚É–ò•¨—Ö@‚Í—LŒø‚©HDŽ¡—ÃC82: 2994-2999, 2000D ’†ŽR—ˆê˜YCŽR’†@CC“ûˆäL•vCàV–ìáÁlFŠ¥‚ê‚ñkŒ^‹·SÇ‚©‚ç‹}«S‹Ø[Ç‚Ö@‚»‚Ì”wŒi‚Æ“Á’¥DJ Cardiol 36 Suppl.I: 124, 2000. ’†ŽR—ˆê˜YC“ûˆäL•vCàV–ìáÁlFŠ¥ó“®–¬Ž¾Š³‚ÆŠ¥ó“®–¬ÎŠD‰»‚ÌŠÖŒW@2,000—á‚ÌŒoŒ±‚©‚çDJ Cardiol 36 Suppl.I: 248, 2000. “¡“c—SŽŸCì–¼ˆê˜NCŽç’Jº•FC‹g]_ˆê˜YC•x“c®•FC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñ»ERCPŒãäX‘Ÿ‰Š‚Í—\–h‚Å‚«‚é‚Ì‚©HDŽ¡—ÃC82: 1443-1450, 2000D “¡“c—SŽŸCì–¼ˆê˜NCŽç’Jº•FC‹g]_ˆê˜YC•x“c®•FC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñ¼‹}«äX‰Š‚ÌŽ¡—Â͒`”’•ª‰ðŽ_‘f‘jŠQ܂͕K—v‚©HDŽ¡—ÃC82: 1841-1848, 2000D ¼“c—æŒ\C“¡“c—SŽŸC•x“c®•FC‹g]_ˆê˜YCŽç’Jº•FCì–¼ˆê˜NC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñ¾’_Δ­ì‚ɃuƒXƒRƒpƒ“‚Í—LŒø‚©H’_”X‰Š‚Ö‚Ìi“W—\–h‚ɉ½‚ª—LŒø‚©HDŽ¡—ÃC82: 2225-2231, 2000D Ž“c‘×sC–Ø‘ºˆê—YF‹~–½‹~‹}—̈æ‚É‚¨‚¯‚éPCPSDW’†Ž¡—ÃC9: 1005-1014, 2000. X@—R—YC”~‘º@•qC’š@@èdF”MƒVƒ‡ƒbƒN’`”’Ž¿‚Æ“®–¬d‰»Ç‚ɂ‚¢‚ÄD—Õଂƌ¤‹†C78: 319-322, 2000. Žç’Jº•FCì–¼ˆê˜NC‹g]_ˆê˜YC“¡“c—SŽŸC•x“c®•FC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñ½Helicobacter pyloriœ‹Û‚ÍCNSAID’×ᇂ̗\–h‚É—LŒø‚©HDŽ¡—ÃC82: 2025-2032, 2000D ˆÀ“c@Œ³F‹U«ƒAƒ‹ƒhƒXƒeƒƒ“ÇD—Õ°ˆãC26:1321-1323, 2000. ˆÀ“c@Œ³C”~‘º@•qFACE‘jŠQ–ò‚ÆtzŠÂD“ÁWtzŠÂŋ߂̘b‘èCzŠÂŠí‰ÈC47: 60-66, 2000. ‹g]_ˆê˜YCì–¼ˆê˜NC•x“c®•FCŽç’Jº•FC“¡“c—SŽŸC‹{–{ˆêsF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñ¸­—ʃAƒXƒsƒŠƒ“‚Í’×ᇂ̊댯ˆöŽq‚©HDŽ¡—ÃC82: 153-160, 2000D ‹g]_ˆê˜YC“¡“c—SŽŸCŽç’Jº•FCì–¼ˆê˜NC‹{–{ˆêsC”~‘º@•qF‰½‚ª³‰ðHÁ‰»ŠíŽ¡—ÃDEBM‚ÅŒŸØñÀH“¹Ã–¬Šà”j—ô‹}«Šú‚ÌŽ¡—ÃDŽ¡—ÃC82: 2588-2595, 2000D 1999”N•âˆâ ‰–”V“ü—mFt‹@”\áŠQ‚ð‡•¹‚·‚邌Œˆ³Ž¡—ÃDƒƒfƒBƒJƒ‹’©“úC28: 11-13, 1999.
i’˜@@‘j Îã—FÍC”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|¬ˆö˜_‚Æ•a‘Ô¶—@Œ´ˆöŒó•âˆâ“`Žq@ƒAƒ“ƒWƒIƒeƒ“ƒVƒm[ƒQƒ“ˆâ“`Žq@‚ŒŒˆ³ãŠªC507-510C“ú–{—Õ଎ÐC“Œ‹žC2000. Îã—FÍC”~‘º@•qF’Pˆêˆâ“`Žq‚ªŒ´ˆö‚Æl‚¦‚ç‚ê‚邌Œˆ³@‚ŒŒˆ³‰ºŠªC649-654C“ú–{—Õ଎ÐC“Œ‹žC2000. Îã—FÍC”~‘º@•qFƒjƒtƒFƒWƒsƒ“‚ÆŒŒ“œ’lã¸D‘æ‚Q”Å‚±‚Ì–ò‚Ì‚±‚Ì•›ì—pD254-255CˆãŽ•–òo”ÅC“Œ‹žC2000. Šâ’ØkôC”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|Ž¡—Ã@–ò•¨—Ö@@‚»‚Ì‘¼@‚ŒŒˆ³‰ºŠªC183-186C“ú–{—Õ଎ÐC“Œ‹žC2000. A“c^ˆê˜YC”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|¬ˆö˜_‚Æ•a‘Ô¶—@zŠÂ“®‘Ô@––½zŠÂ“®‘Ô@‚ŒŒˆ³ãŠªC340-344C“ú–{—Õ଎ÐC“Œ‹žC2000. ”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|—Õ°@ˆâ“`Žqf’f‚̉”\«@‚ŒŒˆ³ãŠªC632-637C“ú–{—Õ଎ÐC“Œ‹žC2000. ŠC˜V–¼r–¾C“à–ì˜aŒ°C”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|¬ˆö˜_‚Æ•a‘Ô¶—@Œ´ˆöŒó•âˆâ“`Žq@bƒAƒhƒŒƒiƒŠƒ“Žó—e‘̈â“`Žq@‚ŒŒˆ³ãŠªC546-550C“ú–{—Õ଎ÐC“Œ‹žC2000. ŠC˜V–¼r–¾C”~‘º@•qFb ŽÕ’f–ò‚ÆŽ‰Ž¿‘ãŽÓˆÙíD‘æ‚Q”Å‚±‚Ì–ò‚Ì‚±‚Ì•›ì—pD328-330CˆãŽ•–òo”ÅC“Œ‹žC2000. ŠC˜V–¼r–¾CŠâ’ØkôC”~‘º@•qFb ŽÕ’f–ò‚Ì•ªŽq‹@\Db ŽÕ’f–ò‚Ì‚·‚ׂÄC31-38Cæ’[ˆãŠwŽÐC“Œ‹žC2000. ‘å’ËŒ[ŽqC’zŽR‹vˆê˜YC–ì‘ò’¼Ž÷F–{‘Ô«‚ŒŒˆ³Ç|Ž¡—Ã@–ò•¨—Ö@@~ˆ³–ò‚Ì•¹—p@‚ŒŒˆ³‰ºŠªC198-202C“ú–{—Õ଎ÐC“Œ‹žC2000. –ØŒ´@ŽÀC”~‘º@•qFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀŽó—e‘ÌhR–ò‚Ì•›ì—p‚ÆŽg—pã‚Ì’ˆÓD‰¬Œ´r’jC‰Ž“c‹’jC‰iˆä—ÇŽOC“ú˜a“c–M’jC“¡“c•q˜Y•ÒuSŒŒŠÇŒn޾г‚ƃŒƒjƒ“EƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn|V¢‘ãƒAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀŽó—e‘ÌhR–ò‚É‚æ‚錟Ø|vD225-231Cæ’[ˆãŠwŽÐC“Œ‹žC2000. –ØŒ´@ŽÀC”~‘º@•qFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀŽó—e‘̃uƒƒbƒJ[‚̈ʒu•t‚¯DƒAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀŽó—e‘̃uƒƒbƒJ[D103-110C“ú–{ˆãŠwo”ÅC“Œ‹žD –ØŒ´@ŽÀC”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|Ž¡—Ã@–ò•¨—Ö@@ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–ò@‚ŒŒˆ³‰ºŠªC135-139C“ú–{—Õ଎ÐC“Œ‹žC2000. –Ø‘ºˆê—YC¬›‰ë”üFŒŒð—n‰ð—Ö@‚Ì•›ì—pDzŠÂŠí‰ÈC47: 118-125C‰ÈŠw•]˜_ŽÐC2000. ‹vŽœ’¼ŒõC”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|Ž¡—Ã@–ò•¨—Ö@@”ñ~ˆ³–ò‚Æ‚Ì‘ŠŒÝì—p@‚ŒŒˆ³‰ºŠªC189-192C“ú–{—Õ଎ÐC“Œ‹žC2000. Œã“¡‰pŽiCZ“cWˆêF–{‘Ô«‚ŒŒˆ³Ç|¬ˆö˜_‚Æ•a‘Ô¶—@’†•_ŒoŒn‚¨‚æ‚ÑŒðŠ´_ŒoŒn@‚ŒŒãŠªˆ³C285-291C“ú–{—Õ଎ÐC“Œ‹žC2000. ¬—ÑrˆêC”~‘º@•qCŒË’J‹`KF–{‘Ô«‚ŒŒˆ³Ç|¬ˆö˜_‚Æ•a‘Ô¶—DŒ´ˆöŒó•âˆâ“`Žq@aƒAƒhƒŒƒiƒŠƒ“Žó—e‘̈â“`Žq@‚ŒŒˆ³ãŠªC540-545C“ú–{—Õ଎ÐC“Œ‹žC2000. ‰–”V“ü—mFzŠÂŠíŒn޾г‚̊댯ˆöŽqŠÇ—‚Æ‚ŒŒˆ³Ž¡—ÃD1-261C“Œ‹žˆãŠwŽÐC2000. ‰–”V“ü—mC‰–”V“ü‰·FƒJƒŠƒEƒ€•⋋܂ƃJƒŠƒEƒ€•ÛŽÜ—˜”A–òD‚±‚Ì–ò‚Ì‘¼Ü•¹—p•›ì—p|‘æ‚Q”ÅC46-49CˆãŽ•–òo”ÅC“Œ‹žC2000. ‰–”V“ü—mC–ØŒ´@ŽÀF“§Í—Ö@‚É‚¨‚¯‚é—lX‚È‹^–â‚É“š‚¦‚é|ƒVƒŠ[ƒY‚RDACE‘jŠQ–ò‚Ì~ˆ³‹@˜‚Æ•ª—ÞD116-121CƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐC‘åãC2000. ‰–”V“ü—mFDrug treatment IIID2000 ISH highlights. 142-149CƒƒfƒBƒJƒ‹ƒWƒƒ[ƒiƒ‹ŽÐC“Œ‹žC2000. ‰–”V“ü—mC“¡“cF”VF–«t•s‘S‚Ì–ò•¨—Ö@D~ˆ³–òC75-79C“Œ‹žˆãŠwŽÐC“Œ‹žC2000. ‚–ØM‰ÃF–{‘Ô«‚ŒŒˆ³Ç|—Õ°@S’´‰¹”gŠŒ©@‚ŒŒˆ³ãŠªC736-739C“ú–{—Õ଎ÐC“Œ‹žC2000. ‚è@òC”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|Ž¡—Ã@–ò•¨—Ö@@CahR–ò@‚ŒŒˆ³‰ºŠªC127-132C“ú–{—Õ଎ÐC“Œ‹žC2000. ‚è@òC‰–”V“ü—mFƒŒƒjƒ“CƒAƒ“ƒWƒIƒeƒ“ƒVƒ“CƒAƒ‹ƒhƒXƒeƒƒ“CAnnual Review“à•ª”åE‘ãŽÓ2000D250-255C’†ŠOˆãŠwŽÐC2000. “c‘ºŒ÷ˆêC”~‘º@•qFˆâ“`ŽqŽ¡—Â̗հ‰ž—pD‚ŒŒˆ³‰ºŠªC348-353C“ú–{—Õ଎ÐC“Œ‹žC2000. “c‘ºŒ÷ˆêCÎã—FÍC”~‘º@•qFˆâ“`Žq•ψÙ@ƒAƒ“ƒWƒIƒeƒ“ƒVƒm[ƒQƒ“ˆâ“`ŽqD‚ŒŒˆ³ƒiƒrƒQ[ƒ^[D56-57CƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐC“Œ‹žC2000. ’zŽR‹vˆê˜YCí¼®ŽuC‘å’ËŒ[ŽqF–{‘Ô«‚ŒŒˆ³Ç|Ž¡—Ã@–ò•¨—Ö@@~ˆ³–ò‚ÌŠJŽn‚Æ‘I‘ð@‚ŒŒˆ³‰ºŠªC193-197C“ú–{—Õ଎ÐC“Œ‹žC2000. ’‡àVˆê˜YC”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|¬ˆö˜_‚Æ•a‘Ô¶—@Œ´ˆöŒó•âˆâ“`Žq@‚»‚Ì‘¼‚ÌŠÖ˜Aˆâ“`Žq@‚ŒŒˆ³ãŠªC588-590C“ú–{—Õ଎ÐC“Œ‹žC2000. ‹´–{’B•vC”~‘º@•qF’ZŽwǂ𔺂¤‚ŒŒˆ³ÇD‚ŒŒˆ³‰ºŠªC679-683C“ú–{—Õ଎ÐC“Œ‹žC2000. ‰Ô“cWˆêC”~‘º@•qFŽOŠÂŒnR‚¤‚–òD‚ŒŒˆ³‰ºŠªC633-637C“ú–{—Õ଎ÐC“Œ‹žC2000. •½˜aLmC”~‘º@•qFƒvƒƒXƒ^ƒTƒCƒNƒŠƒ“‡¬y‘f|ˆâ“`Žq•ψقƈâ“`ŽqŽ¡—Ẩ”\«|‚ŒŒˆ³‰ºŠªC696-699C“ú–{—Õ଎ÐC“Œ‹žC2000. •½˜aLmC”~‘º@•qFWHO/ISH‚ŒŒˆ³Ž¡—ÃŽwji‰ü’ù”Åj‚É‚¨‚¯‚éA IIŽó—e‘ÌhR–ò‚̈ʒu•t‚¯D”‹Œ´r’jC‹e’rŒ’ŽŸ˜YC‰Ž“c‹’jC“‡–{˜a–¾C“ú˜a“c–M’jC‹{è•v•ÒuA IIŽó—e‘ÌhR–ò‚Ì‚·‚ׂÄv‘æ‚Q”ÅC318-321Cæ’[ˆãŠwŽÐC“Œ‹žC2000. •½˜aLmC”~‘º@•qF–{‘Ô«‚ŒŒˆ³DŠÅŒì‚Ì‚½‚ß‚ÌÅVˆãŠwuÀ‘æ‚UŠª@t‘Ÿ‚Æ‚ŒŒˆ³C243-253C’†ŽR‘“XC“Œ‹žC2000D •½˜aLmFGenetics IIiSession 5Aj. ISH Highlights 2000C52-56CƒƒfƒBƒJƒ‹EƒWƒƒ[ƒiƒ‹ŽÐC“Œ‹žC2000D “¡“cF”VC”~‘º@•qFb ŽÕ’f–ò‚ƈ«–²D‘æ‚Q”Å‚±‚Ì–ò‚Ì‚±‚Ì•›ì—pD320-322CˆãŽ•–òo”ÅC“Œ‹žC2000. ŽO•–¾•vC”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|Ž¡—Ã@–ò•¨—Ö@@¸__ŒoáŠQ@‚ŒŒˆ³‰ºŠªC154-157C“ú–{—Õ଎ÐC“Œ‹žC2000. “ìàVN‰îC”~‘º@•qFƒjƒtƒFƒWƒsƒ“‚Æ‹}Œƒ‚ÈŒŒs“®‘Ԃ̕ω»D‘æ‚Q”Å‚±‚Ì–ò‚Ì‚±‚Ì•›ì—pD250-252CˆãŽ•–òo”ÅC“Œ‹žC2000. “ìàVN‰îC”~‘º@•qF‚ŒŒˆ³ÇгŽÒ‚ÌŽèpC–ƒŒD‚ŒŒˆ³‰ºŠªC388-391C“ú–{—Õ଎ÐC“Œ‹žC2000. ‹{“‡‰hŽ¡Cž\‹v•ÛCF–{‘Ô«‚ŒŒˆ³Ç|—Õ°@Ц—âŽhŒƒ@‚ŒŒˆ³ãŠªC667-669C“ú–{—Õ଎ÐC“Œ‹žC200.0 ‹{“‡‰hŽ¡FBlood pressure management and analysis. 2000 ISH HIGHTLIGHTS-SESSION 4C, 46-51CƒƒfƒBƒJƒ‹ƒWƒƒ[ƒiƒ‹ŽÐC2000. ˆÀ“c@Œ³C”~‘º@•qFBartterÇŒóŒQCGitelmanÇŒóŒQD’†ˆä—˜º•ÒuŒŸ¸’l‚݂̂©‚½‰ü’è2”ÅvD137-141C’†ŠOˆãŠwŽÐC“Œ‹žC2000. ˜a“c@“ÄC”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç|Ž¡—Ã@–ò•¨—Ö@@”ç•†Ž¾Š³@‚ŒŒˆ³‰ºŠªC172-175C“ú–{—Õ଎ÐC“Œ‹žC2000. 1998”N•âˆâ “c‘ºŒ÷ˆêC”~‘º@•qC‚è@òCΈäác’jD‘gDƒŒƒjƒ“|ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn‚©‚ç‚Ý‚½ŒŒŠÇ•ǘV‰»‹@˜‚Æ‚ŒŒˆ³‚Ƃ̊֌W‚ɂ‚¢‚ẲðÍ|ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀ‚É‚æ‚錌ŠÇ•½ŠŠ‹Ø×–EƒtƒBƒuƒƒlƒNƒ`ƒ“ˆâ“`Žq”­Œ»’²ß‚Ì•ªŽqƒƒJƒjƒYƒ€‚ɂ‚¢‚Ă̌Ÿ“¢D‰¡•lŽs“Á’茤‹†Ž–‹Æ•ñ‘u˜V‰»E¶–½Œ»Û‚ÉŠÖ‚·‚錤‹†|˜V”N«Ž¾Š³EŠà‚̬ˆöE‰uŠwEŽ¡—ÃvC16-20C1998
iŠw‰ï”­•\j Shionoiri H, Takasaki I, Minamisawa K, Ueda S: Whether trandolaprilat, an ACE inhibitor, is excreted in bile via an ATP-dependent active transportericMOATj? Symposium of Quantitative Morecular Pharmacology and Drug Disco-very, Kona, 2000, 2. Hibi K, Fitzgerald PJ, Honda Y, Asakura Y, Tanaka S, Uchiyama T, Matsubara T, Oda H, Kato J, Kato O, Ueda K, Kijima M, Handen CE, Yock PG, Tamai H, Aizawa T. For the DESIRE Investigators: Impact of coronary debulking prior to stenting versus conventional stenting on early outcome: Initial IVUS findings. 49th Annual Scientific Session of the American College of Cardiology, Anaheim, California, 2000, 3. Toda N, Ishikawa T, Tsunematsu T, Nozawa N, Kobayashi I, Miyamoto K, Tsukiyama H, Sumita S, Kimura K, Umemura S: Doppler index and plasma level of atrial natoriuretic hormone are improved by optimizing atrioventricular delay in atrioventricular block patients with implanted DDD pacemakers. 49th American College of Cardiology, Anaheim, 2000, 3. Chen Q, Chen YE, Tamura K, Pratt RE: Identification of a cGMP responsive element in smooth muscle myosin promoter. Experimental Biology 2000, FASEB Meeting, San Diego, 2000, 4. Ishikawa I, Sugano T, Sumita S, Toda N, Kosuge M, Kobayashi I, Kuji N, Kimura K, Tochikubo O, Usui T, Umemura S: Prediction of the optimal atrioventricular delay by the QT sensor in patients with implanted DDDR pacemakers: 21th North American Society of Cardiac Pacing and Electrophysiology, Washington DC, 2000, 5. Miyajima E, Shigemasa T, Kawano Y, Okumura J, Umemura S: Troglitazone reduces sympathetic nerve activity in patients with hyperinsulinemia and hypertension. 15th Annual Scientific Meeting of American Society of Hypertension, New York, 2000, 5. Miyajima E, Shigemasa T, Kawano Y, Endo T, Umemura S: Morning blood pressure surge derives from central sympathetic nerve activity but not from parasympathetic activitiy. 15th Annual Scientific Meeting of American Society of Hypertension, New York, 2000, 5. Shigemasa T, Miyajima E, Tochikubo O, Umemura S: Neurohormonal effects on left ventricular mass in patients with essential hypertension: 15th Scientific Meeting of the American Society of Hypertension, New York, 2000, 5. Ishikawa I, Sugano T, Sumita S, Toda N, Kosuge M, Kobayashi I, Kimura K, Tochikubo O, Usui T, Umemura S: Optomal atrioventricular delay setting determined by the QT sensor of an implanted DDDR pacemaker. 12th International Congress Cardiostim 2000, Nice, 2000, 6. Toda N, Ishikawa T, Tsunematsu T, Nozawa N, Kobayashi I, Miyamoto K, Tsukiyama H, Sumita S, Kimura K, Umemura S: Doppler index and plasma level of atrial natriuretic hormone are improved by optimizing atrioventricular delay in atrioventricular block patients with implanted DDD pacemakers. 12th International Congress Cardiostim2000, Nice, 2000, 6. Kimura K, Kosuge M, Tsukahara T, Ishikawa T, Tochikubo O, Umemura S: The difference in time to reperfusion between emergency cardiovascular center and community hospitals in acute myocardial infarction. 15th International congress on fibrinolysis and proteolysis, Hamamatu, 2000, 6. Scholten MF, Gottfridsson C, Ishikawa T, Defaye P, Wesselink WA: AV delay optimization optimization through measurement of the QT interval-study design and initial results. 12th International Congress Cardiostim, Nice, 2000, 6. Shionoiri H, Minamisawa K, Takizawa T, Takasaki I: Clinical advantage of perindopril on microalbuminuria is similar to temacapril in essential hypertension. 7th World Conference on Clinical Pharmacology and Therapeutics, Florence, 2000, 7. Shionoiri H: Effect of treatment with ACE inhibitor on microalbuminuria. The International Editorial Conference of Clinical Pharmacokinetics, Nice, 2000, 7. Shionoiri H, Takasaki I, Takizawa T, Sugimoto K: Effects of renin-angiotensin sysmtem blockade and dietary salt intake on left ventricular hypertrophy in rats. Half-day Conference focused on Advances in RAS Blockade and Management of Cardiovascular Disease, New York, 2000, 8. Shionoiri H, Takasaki I, Minamisawa K, Ueda S, Ishiduka H, Suzuki h, Sugiyama Y: Whether trandolaprilat, an ACE inhibitor, is excreted in bile via an ATP-dependent active transportericMOATj? 18th Scientific Meeting of the International Society of Hypertension, Chicago, 2000, 8. Shionoiri H: Effect of ACE inhibitors on microalbuminuria. Renin Research in the 21st Century, Vancouver, 2000, 8. Hirawa N, Uehara Y, Gomi T, Ikeda T, Urade Y, Seiki K, Umemura S: Prostaglandin D synthase in hypertensives with renal impairement 18th Scientific Meeting of the International Society of Hypertension, Chicago, 2000, 8. Hirawa N, Uehara Y, Gomi T, Ikeda T, Urade Y, Oda H, Umemura S: Urinary Prostaglandin D synthase in hypertensives with diabetes mellitus. 18th Scientific Meeting of the International Society of Hypertension, Chicago, 2000, 8. Ueda S, Maemoto S, Wada A, Brosnihan KB, Umemura S: Angiotensini1-7jpotentiates vasodilating effect of bradykinin in man.i2000j18th Scientific Meeting of International Scoiety of Hypertension. Chicago, USAiPoster presentationj Kuji T, Hasegawa K, Yasuda G, Shimura G, Umemura S, Tochikubo O: Autonomic imbalanace and loss of nocturnal decline of blood pressure in diabetic patients with nephrology. 11th International Congress of Endocrinology, Sydney, 2000, 10. Shionoiri H, Takasaki I, Minamisawa K, Ueda S, Ishiduka H: Question whether trandolaprilat, an ACE inhibitor, is excreted in bile via an ATP-dependent active transporter icMOATj? The Conference on Clinical Pharmacology and New Drug Development, Hawaii, 2000, 10. Wada A, Ueda S, Maemoto S, Kuji N, Umemura S: Angiotensin II attenuates vasodilatation induced by No-donor, Glyceryl Trinitrate: Role of super oxide and angiotensin type 1 receptor. 54 th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Washington DC, 2000, 10. Tamura K, Chen YE, Lopez-Ilasaca M, McEwan P, Sales V, Anderson LM, Horiuchi M, Dzau VJ, and Pratt RE: A novel role for the nuclear receptor LXRalpha in human renin gene expression. 73rd Scientific Sessions 2000, American Heart Association, New Orleans, 2000, 11. Lopez-Ilasaca M, Tamura K, Pratt RE, and Dzau VJ: Chara-cterization of ATRAP as a novel partner of angiotensin II type 1 receptor. 73rd Scientific Sessions 2000, American Heart Association, New Orleans, 2000, 11. Anderson LM, Hopfner RL, Tamura K, Dzau VJ, and Pratt RE: Genomic analysis of cAMP regulated gene expression in cultured mouse kidney juxtaglomerular cells. 73rd Scientific Sessions 2000, American Heart Association, New Orleans, 2000, 11. Hibi K, Honda Y, Suzuki T, Hayase M, Suzuki T, Hosokawa H, Yeung AC, Yock PG: Effects of post intervention atherosclerotic plaque burden on neoingimal proliferation. Scientific Sessions 2000, American Heart Association, New Orleans, Louisiana, 2000, 11. Miyajima E, Shigemasa T, Endo T, Iwasawa Y, Hongo Y, Okuda J, Kobayashi I, Kosuge M, Ishikawa T, Umemura S: Morning blood pressure surge derives from central sympathetic drive and is blunted by clonidine before sleep. 73rd Scientific Sessions 2000, American Heart Association, New Orleans, 2000, 11. Defaye P, Ishikawa T, Winter S, Gottfriendsson C, Cavernac P, Wesseliink W, on behalf of the QADO: Optimization of the AV delay through measurement of the QT interval. Study design and initial results. 9th International Symposium on Progress in Clinical Pacing, Rome, 2000, 12. Ishikawa T, Sumita S, Kimura M, Kosuge M, Kobayashi I, Nakagawa T, Matsushita K, Ohkusu Y, Kimura K, Usui T, Umemura S: Long-term follow-up in patients in patients with intra-Hisian atrioventricular block. 9th International Symposium on Progress in Clinical Pacing, Rome, 2000, 12. ìè“TŽqC‹`ˆä@÷C´…’q–¾CàV“c—æ–¯C¬‹v•Û‹`˜aC¬ì‰pKF•ϫÖ¬ƒOƒ‰ƒtƒg‚ɑ΂µƒXƒeƒ“ƒg‚ð—¯’u‚µno-reflow‚ƂȂèS‹Ø[Ç‚ð‡•¹‚µ‚½‚P—áD“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïƒEƒBƒ“ƒ^[ƒ~[ƒeƒBƒ“ƒOC·‰ªC2000, 1. ‰ª@‘ìŽuC‚‹´‰„˜aCŽRŒû’ŽqC¼Œ´@¡C“c’†”ü”¿C™‘òd•vCL–ìŒ\ŽiC‹e’r’B–çC–ì‘ò••vCŽO’J—E—YC”~‘º@•qFQGS‚ÆpFAST‚̃tƒ@ƒ“ƒgƒ€‚ð—p‚¢‚½Šî‘b“IŒŸ“¢D‘æ52‰ñ“ú–{ŠjˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïC“Œ‹žC2000, 1. ì–{‰ë”üC‚‹´‰„˜aC¼Œ´@¡C‘å’|‰p“ñC•P–ìG˜NC”ªŒLG”VC‰Pˆä@FFDual Isotope Dynamic SPECT‚É‚æ‚é123 I-BMIPP, 201Tl‚ÌEarly kinetics‚ÌŒŸ“¢D‘æ52‰ñ“ú–{ŠjˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïC“Œ‹žC2000, 1. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC´…@½C–{‹½—mˆê˜YCd­’©•FCŠâàV—S“ñC¬—Ñ@òCÄ“¡r•FC‰Ô“cWˆêC‰œ“c@ƒC”~‘º@•qF‹}«S‹Ø[Ç‚ÅHDLƒRƒŒƒXƒeƒ[ƒ‹‚ɑ΂·‚鑃RƒŒƒXƒeƒ[ƒ‹”ä‚É‚æ‚è—Õ°‘œ‚¨‚æ‚ÑŠ¥“®–¬‘¢‰eŠŒ©‚͈قȂéD‘æ16‰ñŽñ“sS‘Ÿ•aƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXC“Œ‹žC2000, 1. ‰–”V“ü—mF~ˆ³–òŽ¡—Ẫ|ƒCƒ“ƒg|ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–òDƒ‰ƒWƒI’Z”gC“Œ‹žC2000, 1. ‰–”V“ü—mFtáŠQ‚ð‡•¹‚·‚邌Œˆ³Ž¡—ÃD’©“úˆãŠwƒZƒ~ƒi[C…ŒËC2000, 2. ‰–”V“ü—mF‚މŒŒÇŽ¡—ÂÆzŠÂŠí޾гD‰¡•l“à‰ÈŠwu‰‰‰ïC‰¡•lC2000, 2. ¬‹v•Û‹`˜aC‘å–ìˆÀ”üCˆÉŠÖ»ŠGCìŒûŒåŽjCìŒû’|’jF’·Šú¶‘¶‚µ‚¦‚½’PS–[‚Ì‚P–UŒŸ—áD‘æ177‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 2. ‘å“í‘×¶C•P–ìG˜NC‰Pˆä@FC”ªŒLG”VCX“c—L‹IŽqC™ŽR@”£C¶‹î‰pŽqC”–Ø­LFS‹Ø[Ç‚ð”­Ç‚µ‚½Š¥“®–¬Šg’£Ç‚ð—L‚·‚é”ì‘åŒ^S‹ØÇ‚Ì‚P—áD‘æ175‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 2. ”~‘º@•qF‚ŒŒˆ³‚ÌŒ´ˆöˆâ“`Žq‚ÆŽ¡—ÃUp dateD’©“úˆãŠwƒZƒ~ƒi[CŽR—œC2000, 2. ¬ˆäŽè—TˆêC‘å–ìˆÀ”üC‹g“c@“OC•Ÿˆä˜aŽ÷CìŒû’|’jC“c’†‰p•äCˆÀ–쌛ˆêC’·’JìÍ—YF–¢”j—ô‚Å”­Œ©‚³‚ꂽValsalva‘å“®–¬áŽ‚Ì‚PŽèp—áD‘æ175‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 2. Œã“¡@‹œC´–ì’©”ŽC^“‡—YˆêC‘¾Œ´@—mCŒÃ’J@—ºCX@ˆê”ŽC“c‘º@”ŽC‹ŒE—˜–¾C”~‘º@•qF–å–¬Žîá‡Çð‚𔺂Á‚½ŠÌ×–EŠà‚ÉPEIT‚ðs‚¢pŒã‹CŠÇŽxšb‘§‚ð‡•¹‚·‚é‚àŒø‰Ê“I‚Å‚ ‚Á‚½‚P—áD‘æ258‰ñ“ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”—á‰ïC‘å‹{C2000, 2. ¬—ÑrˆêC–ØŒ´@ŽÀC”~‘º@•qFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“II1aŒ^Žó—e‘̈â“`ŽqŒ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚郌ƒjƒ“|ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œnˆâ“`Žq”­Œ»‚̕ω»D‘æ‚T‰ñƒAƒ“ƒWƒIƒeƒ“ƒVƒ“ƒJƒ“ƒtƒ@ƒŒƒ“ƒXC‘åãC2000, 2. ²X–Ø—´C–k‘º@–LCª–{–LŽ¡C’ËŒ´Œ’ŒáC–Ø‘ºŽõGC’‡àV»ŽqC“c’†@õC“úŒG‹e”䎙FˆùŽðŒã”­Ç‚µC—¼SŽº•lj^“®ˆÙí‚ð’æ‚µ‚½‚½‚±‚‚ڌ^S‹ØÇ‚Ì‚P—áD‘æ175‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 2. àV–ì^lC“ûˆäL•vC’†ŽR—ˆê˜YCŽR’†@CC‰Í‡Ë—YF‚½‚±‚‚ڗlS‹ØáŠQ‚Ì‚Q—á|‰EŽº‘¢‰e‚ÆS‹Ø¶ŒŸ‘œD‘æ175‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 2. d­’©•FC–Ø‘ºˆê—YC‰Ž“n@—ÍC´…@½C–{‹½—mˆê˜YCŠâàV—S“ñC¬—Ñ@òC¬›‰ë”üC’†ì@‹BC’†ŒËì’m—ŠCÄ“¡r•FC‰œ“c@ƒC‰Ô“cWˆêC‹{“‡‰hŽ¡CÎì—˜”VC”~‘º@•qFÄ‘a’ʗÖ@Œã‚Ì•p‰ñ‚ÉoŒ»‚·‚éSŽº×“®‚ɉ–Ž_ƒjƒtƒFƒJƒ‰ƒ“ƒg‚ª‘tŒ÷‚µ‚½‹}«S‹Ø[ǂ̂P—áD‘æ177‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 2. ™ŽR@”£C”ªŒLG”VC•P–ìG˜NCX“c—L‹IŽqC¶‹î‰pŽqC‘å“í‘×¶C‰Pˆä@FC”–Ø­LCŠâˆä–FOC’†‘ºŒõÆFS–[’†ŠuŒ‡‘¹Ç‚Æ“®–¬ŠÇŠJ‘¶Ç‚ð‡•¹‚µ‚½ˆê¬l—áD‘æ13‰ñ“¡‘òŽs“à‰ÈˆãŠw‰ïC“¡‘òC2000, 2. ’|‘ºmŽuC‰“ŽRTˆêC—Ñ@CˆêC–¼‘q•qOC‰º’ÇŽqC’†”ö³sCX@—TsCª–{³‘¥C’†ì@[C•Ÿˆä˜aŽ÷C‰iŽ@ŒMFˆêŽž“I‰º‘åÖ¬ƒtƒBƒ‹ƒ^[‰º‚ÉŒŒð—n‰ð—Ö@‚ðs‚Á‚½L”Ä«‹}«”xÇðǂ̂P—áD‘æ177‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 2. ’ߌ©—TŽqC’|‰ºN‘ãC™ˆäÍ“ñC‹àŒŽ@—EC—é–ØŒ’ŽiC“‡“c_‘¾CA“ciˆê˜YC‘Šì’ŽjCácŠÔdlCŽR“cº•vC‚–ØM‰ÃFSLE‚ª‹­‚­‹^‚í‚êCt¶ŒŸ‘gD‘œ‚Ådense deposit‚ð”F‚ß‚½’`”’˜Ro«ˆÝ’°Ç‚Ì‚P—áD‘æ33‰ñ_“Þìt‰ŠŒ¤‹†‰ïC‰¡•lC2000, 2. ’†ŠÛ^ŽuC‚“ªŒ’‘¾˜YCŠC˜V–¼r–¾C“à–ì˜aŒ°CŽRŠÝ‚GC´…@‰xC˜aò@“OF¬n•wl‚É”­Ç‚µ‚½•sˆÀ’è‹·Sǂ̂P—áD‘æ175‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 2. –ì‘ò’¼Ž÷Cí¼®ŽuCŒË“cŒ›FC’zŽR‹vˆê˜YF‹}«Š¥ÇŒóŒQ‚ð”­Ç‚µ‚½æ“V«C3Œ‡‘¹Ç‚Æ‚LpiajŒŒÇ‚𔺂¤Žá”NSLE—«‚Ì‚P—áD‘æ175‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 2. ‹g“cŒ\ŽqC–Ø‘ºˆê—YC´…@½CŠâàV—S“ñC–{‹½—mˆê˜YC™ŽR@vC”~‘º@•qFDisopyramide‘å—Ê•ž—pŽž‚Ì—Õ°Œo‰ßFS’âŽ~‚ð‚«‚½‚·‚à•â•zŠÂ‚É‚æ‚è‹~–½‚µ‚¦‚½‚P—áD‘æ‚T‰ñ‹~‹}—̈æ‚É‚¨‚¯‚éPCPS§˜b‰ïC‰¡•lC2000, 2. ŽO’J—E—YFS“d“¯ŠúSPECT QGSTM‰ðÍ”Žw•W‚̑Ó–«‚ÌŒŸ“¢|MIBI‚¨‚æ‚Ñ@TF“Š—^ŒãŽB‘œŠJŽnŽžŠÔ‚Ì‹y‚Ú‚·‰e‹¿|DS‘ŸŠjˆãŠwƒtƒH[ƒ‰ƒ€C“Œ‹žC2000, 3. ‹{“‡‰hŽ¡Cd­’©•FCàV“c—æ–¯Cì–ì–FKCž\‹v•ÛCCΈäác’jC”~‘º@•qF”½ŽË«ŒðŠ´_Œo—}§ì—p‚ɑ΂·‚éACE‘jŠQ–ò‚Ì‹}«‚¨‚æ‚Ñ–«“Š—^‚̉e‹¿D‘æ64‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïC‘åãC2000, 3. Žðˆä­ŽiC¬ì¬ÍCa’J@Œ¤CŽu‘º@ŠxCí“cN•vF–¾‚ç‚©‚ÈS‘©«áŠQ‚𔺂í‚È‚¢ŠÔŽ¿«”x‰Š‚ð‡•¹‚µ‚½MPO-ANCAŠÖ˜At‰Š‚Ì‚P—áD‘æ64‰ñ_“Þ쌧“à‰ÈˆãŠw‰ïC¬“cŒ´C2000, 3. ”~‘º@•qF‚ŒŒˆ³‚̃Rƒ“ƒgƒ[ƒ‹‚ÆŽ¡—ÃD¶ŠˆKе•a—\–hu‰‰‰ïC“Œ‹žC2000, 3. ¶‹î‰pŽqC‰Pˆä@FC”ªŒLG”VC•P–ìG˜NCX“c—L‹IŽqC™ŽR@”£C‘å“í‘×¶C”–Ø­LFbó‘B‹@”\˜´iǂɇ•¹‚µ‚½S•s‘S‚Ì‚P—áD‘æ64‰ñ_“Þ쌧“à‰ÈˆãŠw‰ïC¬“cŒ´C2000, 3. ‰–”V“ü—mFtáŠQ‚ð‡•¹‚·‚邌Œˆ³Ž¡—ÃD’©“úˆãŠwƒZƒ~ƒi[C’ÃC2000, 3. ‰–”V“ü—mF‡•¹‚Ì‚ ‚邌Œˆ³‚ÌŽ¡—ÃD“ì’O”gˆãŽt‰ïu‰‰‰ïC’O“ìC2000, 3. ‚è@òF‚މŒŒÇŽ¡—ÃÅVŽ–îDŽR”V“à»–ò‚މŒŒÇŒ¤C‰ïC‰¡•lC2000, 3. ‚è@òF“®–¬d‰»«Ž¾Š³‚ɑ΂·‚éÅVƒXƒgƒ‰ƒeƒW[DÀ’Óà‰Èˆã‰ïŠwpu‰‰‰ïCÀ’ÃC2000, 4. ”~‘º@•qF‚ŒŒˆ³Ž¡—ÂɊւ·‚éŋ߂̘b‘èDH“cŒ§ƒn[ƒgƒŠƒXƒNu‰‰‰ïCH“cC2000, 4. Îì—˜”VC›–ìW–õCZ“cWˆêC‹e’r”ü–çŽqC’†ì@‹BC‰Ô“cWˆêC¬—Ñ@òC¬›‰ë”üCd­’©•FC‰Ž“n@—ÍC‹vŽœ’¼ŒõC–Ø‘ºˆê—YC”~‘º@•qFDDDRƒy[ƒXƒ[ƒJ[‚ÌQTƒZƒ“ƒT[‚É‚æ‚鎊“Katrioventricular delay‚ÌÝ’èD‘æ64‰ñ“ú–{zŠÂŠíŠw‰ïC‘åãC2000, 4. Îì—˜”VCZ“cWˆêC‹e’r”ü–çŽqC‰Ô“cWˆêC¬—Ñ@òC¬›‰ë”üCd­’©•FC‰Ž“n@—ÍC–Ø‘ºˆê—YC”~‘º@•qF“´•s‘SÇŒóŒQ‚É‚¨‚¯‚éS–[‘e“®‚É‚¨‚¯‚邎ü”gƒJƒe[ƒeƒ‹ÄŽÜp‚¨‚æ‚Ñ“¯Žžƒy[ƒXƒ[ƒJ[Až‚ÝŽèp‚ÌŒŸ“¢D‘æ97‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïC‹ž“sC2000, 4. ìè“TŽqC‹`ˆä@÷C´…’q–¾CàV“c—æ–¯C¬‹v•Û‹`˜aC¬ì‰pKFƒXƒeƒ“ƒgŒãŠg’£‚ɂĊ¥“®–¬úE‚ð”­Ç‚·‚é‚àPerfusion balloon‚ð—p‚¢bail out‚µ‚½‚P—áD‘æ16‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠÖ“ŒbM‰z’n•û‰ïC‚èC2000, 4. Š¿“߉ë•FC¬“‡@~C”nê@Œ’C|’J•Û•vC‘å•@“NCXˆä@Œ÷CˆÀ“c@‘C‹{èrˆêCŒã“¡—tˆêC–ìX–ØGF‹}«S‹Ø[Ç”­Ç‘O‚Ì•a‘Ô‚ÍŒŒð—n‰ð—Ö@Œã‚Ì–«ŠúŽc‘¶‹·ó“x‚ð‹K’è‚·‚é‚©H@‘æ64‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïC‘åãC2000, 4. –Ø‘ºˆê—YF‹}«S‹Ø[Çǂɑ΂·‚éÄ‘a’ʗÖ@‚Í‚¢‚©‚É‚ ‚é‚ׂ«‚©D‘æ64‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïC‘åãC2000, 4. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC´…@½C–{‹½—mˆê˜YCd­’©•FCŠâ‘ò—S“ñC¬—Ñ@òCÖ“¡r•FC’†ŒËì’m—ŠC‰Ô“cWˆêC‰œ“c@ƒC“È‹v•ÛCC”~‘º@•qF‹}«L”Í‘O•Ç’†Šu[ǂɂ¨‚¯‚éaVR—U“±‚ÌST’ቺ‚Ì—Õ°“IˆÓ‹`D‘æ64‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïC‘åãC2000, 4. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC´…@½C–{‹½—mˆê˜YCd­’©•FCŠâ‘ò—S“ñC¬—Ñ@òCÖ“¡r•FC’†ŒËì’m—ŠC‰Ô“cWˆêC‰œ“c@ƒC™ŽR@vCž\‹v•ÛCC”~‘º@•qFHDLƒRƒŒƒXƒeƒ[ƒ‹‚ɑ΂·‚鑃RƒŒƒXƒeƒ[ƒ‹‚Ì”äiTC/HDLj‚©‚ç‚Ý‚½‹}«S‹Ø[Çǂ̗հ‘œ‚̈ႢD‘æ64‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïC‘åãC2000, 4. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC´…@½C–{‹½—mˆê˜YCd­’©•FCŠâ‘ò—S“ñC¬—Ñ@òCÖ“¡r•FC’†ŒËì’m—ŠC‰Ô“cWˆêC‰œ“c@ƒC™ŽR@vCž\‹v•ÛCC”~‘º@•qF‹}«S‹Ø[ÇÄŠÁ—¬Œã‚ÌCK—¬o“®‘ԂƑމ@Žž¶S‹@”\‚Ƃ̊֌WD‘æ64‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïC‘åãC2000, 4. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC´…@½C–{‹½—mˆê˜YCd­’©•FCŠâ‘ò—S“ñC¬—Ñ@òCÖ“¡r•FC’†ŒËì’m—ŠC‰Ô“cWˆêC‰œ“c@ƒC™ŽR@vCž\‹v•ÛCC”~‘º@•qF‹}«S‹Ø[ǂɂ¨‚¯‚é‹}«Šú‚Ì”’ŒŒ‹…‚ÆC”½‰ž«’`”’‚Ì—Õ°“IˆÓ‹`‚Ì‘Šˆá“_D‘æ64‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïC‘åãC2000, 4. d­’©•FC‰Ž“n@—ÍC¬—Ñ@òC¬›‰ë”üC‰Ô“cWˆêCÎì—˜”VC‹{“‡‰hŽ¡C–Ø‘ºˆê—YC”~‘º@•qCž\‹v•ÛCF–{‘Ô«‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚錌ˆ³“ú“à•Ï“®‚ÆDoppler indexiTei indexjD‘æ97‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïC‹ž“sC2000, 4. “cŒ´—Ç—YCˆÀ‘º—Ç’jCœA‰ªŒcŽ¡C‰Ô’J²‹vC‹î‘º˜a—YC’†’J@•qCŽRŠÝ³˜aC‹{•–M•vF‚“x‘m–X•Ù‹t—¬‚É‚¨‚¯‚é‘m–X•Ùˆí’E•”ˆÊ‚É‚æ‚é—Õ°‘œ‚Ì‘ŠˆáD‘æ64‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïC‘åãC2000, 4. “cŒ´—Ç—YCˆÀ‘º—Ç’jC“cŒû“ÖŽjCˆÉ“¡Œ’ˆêC{ŽR˜aOC´…@ÂCŒI“c—²ŽuC‘ŠŒ´’¼•FCŠ™‘qŽj˜YC‹{•–M•vFŠg’£Œ^S‹ØÇ‚É‚¨‚¯‚éSŽº•p”‚Ì“Á’¥D‘æ64‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïC‘åãC2000, 4. “cŒ´—Ç—YC‚–Ø@—mCˆÀ“c@‘CŸN–Ø@ŒåC‚–ØCˆêC‰i’JŒ›ÎC”nê@Œ’C⊪•¶—YC‹ž’JWŒáCŒã“¡—tˆêC»ìŒ«“ñF‰^“®’†‚̓ˑR‚ÌS””’ቺ‚É”º‚¤‰^“®ŽžŠ·‹C”—ʂ̓®‘ԕω»D‘æ64‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïC‘åãC2000, 4. ˜a“c@“ÄCA“c^ˆê˜YC‘O–{’qŽqC”~‘º@•qFƒqƒg’ïRŒŒŠÇ‚É‚¨‚¢‚ÄCƒAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀ‚ÍAT1Žó—e‘Ì‚ð‰î‚µ‚ăjƒgƒƒOƒŠƒZƒŠƒ“CANP‚ÌŒŒŠÇŠg’£ì—p‚ðŒ¸Žã‚³‚¹‚éD‘æ64‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïC‘åãC2000, 4. –{‹½—mˆê˜YC–Ø‘ºˆê—YC‰œ“c@ƒC´…@½CŠâ‘ò—S“ñCÄ“¡r•FC™ŽR@vCŽRŠÝ³˜aC‰Ž“n@—ÍCž\‹v•ÛCCd­’©•FC¬›‰ë”üC¬—Ñ@òCÎì—˜”VC”~‘º@•qF‹}«S‹Ø[ÇÇÓ”CŠ¥“®–¬•a•ς̌`‘Ô‚Í[Ç‘O‹·Sǂ̕a‘œ‚É‚æ‚Á‚ĈقȂ邩|ŒŒŠÇ“àƒGƒR[‚É‚æ‚éŠÏŽ@|@‘æ64‰ñ“ú–{zŠÂŠíŠw‰ïC‘åãC2000, 4. –{‹½—mˆê˜YC–Ø‘ºˆê—YCŠâ‘ò—S“ñCÄ“¡r•FC‰œ“c@ƒC™ŽR@vC‰Ž“n@—ÍC“È‹v•ÛCCd­’©•FC¬—Ñ@òC¬›‰ë”üCÎì—˜”VCŽRŠÝ³˜aCž\‹v•ÛCC”~‘º@•q: ‹}«S‹Ø[ÇÇÓ”CŠ¥“®–¬•a•ς̌`‘Ԃ̓Xƒeƒ“ƒg—¯’u‚É‚æ‚è—ÇD‚ÉŠg’£‚·‚é‚©H|ŒŒŠÇ“àƒGƒR[‚É‚æ‚éŠÏŽ@|@‘æ64‰ñ“ú–{zŠÂŠíŠw‰ïC‘åãC2000, 4. X@—TsC‰“ŽRœÄˆêC—Ñ@CˆêC–¼‘q•qOC‰º’ÇŽqC’†”ö³sCª–{³‘¥C’|‘ºmŽuFƒXƒeƒ“ƒg“àÄ‹·ó‚ɑ΂·‚éPOBA‚Æstent in stent‚Ì”äŠrEŒŸ“¢D‘æ16‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠÖ“ŒbM‰z’n•û‰ïC‚èC2000, 4. X“c—L‹IŽqC‰Pˆä@FC”ªŒLG”VC•P–ìG˜NC™ŽR@”£C‘å“í‘×¶C¶‹î‰pŽqC”–Ø­LF‘ÒŠú“IŠ¥“®–¬ƒXƒeƒ“ƒg—¯’upŒã‚ÌÄ‹·ó‚ÆŒŒ’†Lpiaj”Z“x‚ÉŠÖ‚·‚錟“¢D‘æ97‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïC‹ž“sC2000, 4. X“c—L‹IŽqC‰Pˆä@FC”ªŒLG”VC•P–ìG˜NC™ŽR@”£C”–Ø­LF–«Šú‚Éventricular latency‚ð”F‚ß‚½Ç—á‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ15‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïC“Œ‹žC2000, 5. ‹´–{’B•vC–ØŒ´@ŽÀC¬—ÑrˆêC“¡“cF”VC•½˜aLmCŒË’J‹`KC‚–ØM‰ÃC”~‘º@•qFƒ‰ƒbƒg‘å“®–¬•½ŠŠ‹Ø×–E‚É‚¨‚¯‚élipoxygenaseiLOj‚É‚æ‚éiNOS”­Œ»‚̧ŒäD‘æ43‰ñ“ú–{t‘ŸŠw‰ïŠwp‘‰ïC–¼ŒÃ‰®C2000, 5. •½˜aLmC㌴—_Žu•vC— o—Ç”ŽCD“c_ŽiC´…‹»‰îCŒÜ–¡•üŽqC’r“cŽõ—YC‘å¼r³CŒË’J‹`KC”~‘º@•qFt‘Ÿ•a‚É‚¨‚¯‚郊ƒ|ƒJƒCƒ“Œ^ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“D‡¬y‘f‚Ì“®‘ÔD‘æ43‰ñ“ú–{t‘ŸŠw‰ïC–¼ŒÃ‰®C2000, 5. •H–Ø@’qCŽu˜a’‰ŽuC–쑺³ªFÁ‰»«’×ᇊ³ŽÒ‚ÌŒŒ´pepsinogen’l‚ÆHelicobacter pyloriœ‹ÛŽ¡—ÃŒã‚̕ϓ®‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ39‰ñ“ú–{Á‰»ŠíW’cŒŸfŠw‰ï‘‰ïC•Ÿ‰ªC2000, 5. •H–Ø@’qCŽu˜a’‰ŽuC‰¡ŽR’mŽqC–쑺³ªCŒã“¡@‹œC”~‘º@•qF“®–¬d‰»‚̊댯ˆöŽq‚ɑ΂·‚éHelicobacter pyloriœ‹ÛŽ¡—Ẩe‹¿F‘æ59‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ïC‹ž“sC2000, 5. “cŒ´—Ç—YC“cŒû“ÖŽjC‘Š’ë•ŽiC“cç²NŽqC‚–؉ë•FC{ŽR˜aOC´…@ÂCŒI“c—²ŽuC‘ŠŒ´’¼•FCŠ™‘qŽj˜YC’뉮˜a•vC–©’JŒªŽiCⓌ@‹»C¬—ч“ñ˜YF““ï–hŽ~‘•’u‚Ì“dŽ¥Š±Â‚É‚æ‚èƒy[ƒXƒ[ƒJ[‹@”\•s‘S‚ð”F‚ß‚½‚P—áD‘æ15‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïC“Œ‹žC2000, 5. ¬›‰ë”üC–Ø‘ºˆê—YC‰Ž“n@—ÍC–{‹½—mˆê˜YCŠâ‘ò—S“ñCd­’©•FCÎì—˜”VC¬—Ñ@òCÄ“¡r•FC‰œ“c@ƒC‰Ô“cWˆêC”~‘º@•qF[Ç‘O‹·SÇ—ð‚Æ‰ŠÇ‚ÌŠˆ“®«‚Ƃ̊֌WD‘æ‚R‰ñAP¥MIŒ¤‹†‰ïC“Œ‹žC2000, 5. Îì—˜”VCZ“cWˆêC’†ì@‹BC–Ø‘ºˆê—YC”~‘º@•qFDDR{ƒ‚[ƒhEƒXƒCƒbƒ`‚Í–œ”\‚©|DDDR{ƒ‚[ƒhEƒXƒCƒbƒ`‚ÆDDIR‚Ì”äŠrŒŸ“¢|D‘æ15‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒO“d‹C¶—Šw‰ïAƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€õÁƒy[ƒXƒ[ƒJ[ƒNƒŠƒjƒbƒN‚É‚¨‚¯‚épitfall‚Æ‚»‚Ì‘ÎôC“Œ‹žC2000, 5. “à–ì˜aŒ°FS‘Ÿšb‘§‚Æ‹CŠÇŽxšb‘§‚Æ‚Ì‘Šˆá“_Cf’f‚¨‚æ‚ÑŽ¡—Âɂ‚¢‚ÄD‘æ20‰ñƒAƒŒƒ‹ƒM[šb‘§u‰‰‰ïC‘Š–ÍŒ´C2000, 5. ”~‘º@•qF‚ŒŒˆ³Ž¡—ÂÌŋ߂̘b‘è|‘å‹K–ÍŽŽŒ±‚ð‚Ó‚Ü‚¦‚Ä|D’·–ìŽsˆãŽt‰ïŠwpu‰‰‰ïC’·–ìC2000, 5. Œã“¡@‹œC´–ì’©”ŽC^“‡—YˆêC‘¾Œ´@—mCŒÃ’J@—ºCX@ˆê”ŽC•H–Ø@’qC‰¡ŽR’mŽqCŽu˜a’‰ŽuC”~‘º@•qFˆê”Ê•a‰@‚É‚¨‚¯‚é”N—î‚É‚æ‚é“àŽ‹‹¾‚ð—p‚¢‚½‘å’°Žîᇫ•a•ς̃XƒNƒŠ[ƒjƒ“ƒO‚ÌŽŽ‚ÝD‘æ62‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ïC‹ž“sC2000, 5. Œã“¡@‹œC´–ì’©”ŽC^“‡—YˆêC‘¾Œ´@—mCŒÃ’J@—ºCX@ˆê”ŽC”~‘º@•qFŒo”çŒoŠÌ“I–å–¬“à’YŽ_ƒKƒX’“ü–@•¹—pPEIT‚ª’˜Œø‚µ‚½‚P—áD‘æ259‰ñ“ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”—á‰ïC‰¡•lC2000, 5. ¬—Ñ@òCÎì—˜”VC´…@½C‹g“cŒ\ŽqC‰Ô“cWˆêC‰œ“c@ƒC¬›‰ë”üCŠâ‘ò—S“ñCd­’©•FC›–ìW–õC‰Ž“n@—ÍC–Ø‘ºˆê—YC”~‘º@•qC˜aò@“OFS•s‘SÇó‚ðŒ‡‚«C‚“x–[ŽºƒuƒƒbƒN‚É‚æ‚éAdams-Stokes”­ì‚ðŽåÇó‚Æ‚µ‚½ŽYåñŠú‚É”­Ç‚µ‚½S‹Ø‰Š‚Ì‚P—áD‘æ15‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒO“d‹C¶—Šw‰ïC“Œ‹žC2000, 5. ‰–”V“ü—mCA“c^ˆê˜YC“ìàVN‰îC‚è@òFACE‘jŠQ–òƒyƒŠƒ“ƒhƒvƒŠƒ‹‚Ì–{‘Ô«‚ŒŒˆ³Š³ŽÒ‚ɑ΂·‚é”÷—ʃAƒ‹ƒuƒ~ƒ“”A—}§Œø‰ÊD‘æ41‰ñ“ú–{t‘ŸŠw‰ïC–¼ŒÃ‰®C2000, 5. Žu˜a’‰ŽuC•H–Ø@’qC‰¡ŽR’mŽqC–q—R”üŽqC–쑺³ªCŽç’Jº•FCŒã“¡@‹œCì–¼ˆê˜NC”~‘º@•qFŒŸfã•”Á‰»ŠÇ“àŽ‹‹¾‚É‚¨‚¯‚銴õǂɊւ·‚錟“¢D‘æ39‰ñ“ú–{Á‰»ŠíW’cŒŸfŠw‰ï‘‰ïC•Ÿ‰ªC2000, 5. Žu˜a’‰ŽuC•H–Ø@’qC‰¡ŽR’mŽqC–쑺³ªCŒã“¡@‹œC’†¬˜H‰À“ÞCŽç’J³•FCì–¼ˆê˜YC”~‘º@•qFŒŸfã•”Á‰»ŠÇ“àŽ‹‹¾ŒŸ¸‚É‚¨‚¯‚é’Ááz܂̔äŠrŒŸ“¢|ƒOƒ‹ƒJƒSƒ“‚Ì—p—ÊŒŸ“¢|D‘æ59‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ïC‹ž“sC2000, 5. Z“cWˆêCÎì—˜”VC’†ì@‹BC–Ø‘ºˆê—YC”~‘º@•q: ƒy[ƒXƒ[ƒJ[‚É‚æ‚éS–[«•p”ŒŸo‹@”\‚ÌŒŸ“¢D‘æ15‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒO“d‹C¶—Šw‰ïƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€õÁƒy[ƒXƒ[ƒJ[ƒNƒŠƒjƒbƒN‚É‚¨‚¯‚épitfall‚Æ‚»‚Ì‘ÎôC“Œ‹žC2000, 5. ‚è@òF“®–¬d‰»«Ž¾Š³‚ÌÅVƒXƒgƒ‰ƒeƒW[Di‚މŒŒÇA‚ŒŒˆ³‚ð’†S‚Æ‚µ‚Äj‰¡•l‚މŒŒÇŒ¤‹†‰ïD‰¡•lC2000, 5. ‚è@òFŋ߂̂ŒŒˆ³Çf’fEŽ¡—ÃŽwjDŒöŠJÀ’k‰ïEƒxƒXƒgAIIAƒZƒ~ƒi[D‹à‘òC2000, 6. ‚è@òF“®–¬d‰»«Ž¾Š³—\–h‚ÌÅVí—ª|‚މŒŒÇA‚ŒŒˆ³Ç‚ð’†S‚Æ‚µ‚Ä|D£’J‹æˆãŽt‰ïŠwpu‰‰‰ïD‰¡•lC2000, 6. ‰–”V“ü—mFtáŠQ‚ð‡•¹‚·‚邌Œˆ³Ž¡—ÃDŽl“úŽsŽsˆãŽt‰ïu‰‰‰ïCŽl“úŽsC2000, 6. Ä“¡‰p”VC‚–ØM‰ÃCŠâ’ØkôC¬–ìG“ñC‰Ÿì@mC‹´–{’B•vC“y‹´–õŽuC•½˜aLmC’|‰ºN‘ãC–ØŒ´@ŽÀC–î‰Ô^’mŽqCŒË’J‹`KC”~‘º@•qF’˜–¾‚È‚KŒŒÇ‚Æ™–¬‚ð”F‚ߋً}“§ÍŽ{s‚µ‹~–½‚µ“¾‚½¸_•ª—ô•a‡•¹ŒŒ‰t“§ÍгŽÒ‚Ì‚P—áD‘æ59‰ñ_“ÞìtŒ¤‹†‰ïC‰¡•lC2000, 6. ”~‘º@•qF‚ŒŒˆ³Œ´ˆöˆâ“`Žq‚Æ‚»‚Ì—Õ°‰ž—p‚̉”\«D‘æ29‰ñVŠƒ‚ŒŒˆ³’k˜b‰ïCVŠƒC2000, 6. ”~‘º@•qF‹³ˆçu‰‰@¶ŠˆKе•a‚ƈâ“`Žq|‚ŒŒˆ³‚ð’†S‚É|D‘æ7‰ñ“ú–{ˆâ“`Žqf—Êw‰ïC•l¼C2000, 6. ”~‘º@•qF–{‘Ô«‚ŒŒˆ³Ç‚É‚¨‚¯‚éAngiotensin iAGTjˆâ“`Žq‘½Œ^Ct”A׊ÇRenin-AngiotensinŒniRASj‚ÆAT1Žó—e‘ÌhR–òD‘æ‚P‰ñ‹ãBRASŒ¤‹†‰ïC•Ÿ‰ªC2000, 6. ‰Ÿì@mC‚–ØM‰ÃCŠâ’ØkôC‹´–{’B•vC“y‹´–õŽuC•½˜aLmC’|‰ºN‘ãC–ØŒ´@ŽÀC–î‰Ô^’mŽqCŒË’J‹`KC”~‘º@•qCŒ “¡ŠwŽiF“ªŠW“àŽ¾Š³‚ð‡•¹‚µ‚½ŒŒ‰t“§ÍiHDjгŽÒ‚ɑ΂·‚éƒ}ƒ“ƒjƒg[ƒ‹Ž‘±’“üŒŒ‰tàh‰ß“§ÍiM-HDFj‚Ì—L—p«D‘æ45‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ï‘‰ïC•Ÿ‰ªC2000, 6. –Ø‘ºˆê—YFŽ„‚Ìl‚¦‚鎊“KÄŠÁ—¬—Ö@D‘æ‚Q‰ñThrombolysisŒ¤‹†‰ïC“Œ‹žC2000, 6. àV“c—æ–¯C‹`ˆä@÷C´…’q–¾C¬‹v•Û‹`˜aC¬ì‰pKCìè“TŽqC”‹Œ´‘ŽqC•‹’_FTransradial Intervention•s¬Œ÷—á‹y‚Ñ–¢‘I‘ð—á‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ9‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïC‘å’ÃC2000, 6. d­’©•FC‹{“‡‰hŽ¡C”~‘º@•qFŠg’£Œ^S‹ØÇ—l‚ð’æ‚µS•s‘S‚ð‡•¹‚µ‚½––’[”ì‘åǂ̈ê—áD‘æ73‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ïC‹ž“sC2000, 6. ´…@½C–Ø‘ºˆê—YCÄ“¡r•FC–{‹½—mˆê˜YCŠâàV—S“ñC‰œ“c@ƒC‰Ž“n@—ÍCÎì—˜”VC™ŽR@vC”~‘º@•qFS‹Ø[Ç‹}«Šústent—¯’u’¼‘OŒã‚Ìmyocardial blush grade iMBj•ω»‚Ì—Õ°“IˆÓ‹`D‘æ9‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïC‘å’ÃC2000, 6. ‘ê‘ò—˜ˆêC‘哈N‘×C_ÀTˆê˜YCŒ´@–F‹IC¼‰YŒªˆêF’áƒJƒŠƒEƒ€ŒŒÇ‚É‚æ‚艡–䋨—Z‰ð‚ð‚«‚½‚µ‚½CAPD‚Ì‚P—áD‘æ45‰ñ“ú–{“§ÍˆãŠw‰ï‘‰ïC•Ÿ‰ªC2000, 6. ´…@½CX‘º®“oC“à“cŒh“ñC—é–Ø~ˆêC™ŽR@vCŠâàV—S“ñC‰Ž“n@—ÍC–Ø‘ºˆê—YFƒVƒ“ƒ|ƒWƒEƒ€uáŠQ‘ŸŠí‚ɉž‚¶‚½—LŒø‚ÈŽ¡—Ö@v‹}«”xÇðǂɑ΂·‚éŒo”ç“IlHS”x•â•iPCPSj‚É‚æ‚鎡—×á‚ÌŒŸ“¢D‘æ11‰ñƒoƒCƒIƒƒfƒBƒJƒ‹ƒtƒH[ƒ‰ƒ€C“Œ‹žC2000. ’|‰ºN‘ãC’ߌ©—TŽqCácŠÔdlC‚–ØM‰ÃF“ñd–Œ‚ë‰ßŒŒŸ÷ŒðŠ·—Ö@‚É‚æ‚è”DPŒp‘±‰Â”\‚ƂȂÁ‚½RƒŠƒ“Ž‰Ž¿R‘ÌÇŒóŒQ‡•¹SLE‚̈ê—áD‘æ20‰ñ“ú–{ƒAƒtƒFƒŒ[ƒVƒXŠw‰ï‘‰ïCç—tC2000, 6. •À–Ø—z–¾C•½ˆäç’ÃŽqC‘傟‹`CŽO‰Y^Ž÷C‚–ØM‰ÃF‘̉t—Ê‘ª’è‚É‚æ‚éDry WeightÝ’è‚ÌŒŸ“¢D‘æ45‰ñ“ú–{“§ÍˆãŠw‰ïŠwp‘‰ïC•Ÿ‰ªC2000, 6. •½˜aLmC‹´Œû—²”VC‰““¡W•FC‹´–{’B•vCŠâ’ØkôC–î‰Ô^’mŽqC“y‹´–õŽuC’|‰ºN‘ãC–ØŒ´@ŽÀCŒË’J‹`KC‚–ØM‰ÃC‘å¼r³C㌴—_Žu•vC”~‘º@•qFŒŒ‰t“§ÍгŽÒ‚É‚¨‚¯‚錌Ÿ÷’†ƒŠƒ|ƒJƒCƒ“Œ^ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“D‡¬y‘fiL-PGDSj”Z“x|‚P”NƒtƒHƒ[ƒAƒbƒv|D‘æ45‰ñ“ú–{“§ÍˆãŠwŠwpW‰ïC•Ÿ‰ªC2000, 6. ŽO•–¾•vC—އ‹v•vC”~‘º@•qF‘Œz“®–¬‚É‚¨‚¯‚錌ŠÇƒ‚ƒfƒŠƒ“ƒO|Œz“®–¬ƒGƒR[‚É‚æ‚錟“¢|D‘æ42‰ñ˜V”N•aŠw‰ïCå‘äC2000, 6. ”‹´‘åŽ÷CŠâŸº˜a–çC¬–ì]˜a‘¥F‹}«GVHD‰ñ•œŒã‚Ìœ‘ƒLƒƒ‰ƒ}ƒEƒX‚É‚¨‚¯‚éT×–E‚̉ðÍD‘æ‚S‰ñ–kŠC“¹‘ŸŠíˆÚAƒtƒH[ƒ‰ƒ€CŽD–yC2000, 6. X@—TsC‰“ŽRœÄˆêC—Ñ@CˆêC–¼‘q•qOC‰º’ÇŽqC’†”ö³sCª–{³‘¥C’|‘ºmŽuFƒXƒeƒ“ƒg‚ÌŽí—ÞEŒaE’·‚³‚É‚æ‚éÄ‹·ó—¦‚ÌŒŸ“¢D‘æ‚X‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïC‘å’ÃC2000, 6. ‘O“‡M•FC“à–ì˜aŒ°Ca]—³”nC‚“ªŒ’‘¾˜YCŠC˜V–¼r–¾C’†ŠÛ^ŽuF‰ES•s‘S‚Å”­Ç‚µCƒXƒeƒƒCƒh‚¨‚æ‚іƉu—}§Ü‚̃pƒ‹ƒX—Ö@‚ª’˜Œø‚µ‚½”x‚ŒŒˆ³Ç‡•¹¬‡«Œ‹‡‘gD•a‚Ì‚P—áD‘æ176‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï“Œ‹žC2000, 6. ”ªŒLG”VC‰Pˆä@FC•P–ìG˜NCX“c—L‹IŽqC™ŽR@”£C‘å“í‘×¶C¶‹î‰pŽqCí“cN•vC”–Ø­LF‚—îŽÒS‹Ø[ǂɑ΂·‚édirect-PTCA‚̉Šú‚¨‚æ‚Ñ’·Šú¬Ñ‚ÉŠÖ‚·‚錟“¢D‘æ42‰ñ“ú–{˜V”NˆãŠw‰ïŠwpW‰ïCå‘äC2000, 6. “n•Ó„ŽjC’·’JìŽqC‹vŽœ’‰ŽiCˆÀ“c@Œ³C’|—іζC‹ß“¡Ž¡˜YC”~‘º@•qFŒÇ—§«“à’°œ“®–¬áŽ‚ð‡•¹‚µ‚½“§ÍгŽÒ‚Ì2—áD‘æ45‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïC•Ÿ‰ªC2000, 6. –î‰Ô^’mŽqC¤“c@iC‹´Œû—²”VC‰““¡W•FC“y‹´–õŽuC–ØŒ´@ŽÀC•½˜aLmCŒË’J‹`KC‚–ØM‰ÃCŒI“c˜a•vC”~‘º@•qC‘å¼r³FƒAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀŽó—e‘ÌhR–ò‚É‚æ‚肃wƒ}ƒgƒNƒŠƒbƒg‚ðƒRƒ“ƒgƒ[ƒ‹‚µ‚½ŒŒ‰t“§ÍгŽÒ‚̈ê—áD‘æ45‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïC•Ÿ‰ªC2000, 6. “¡“cF”VC–Ø‘ºˆê—YC¬›‰ë”üCÎì—˜”VC´…@½C™ŽR@vCž\‹v•ÛCC”~‘º@•qF‹}«Š¥ÇŒóŒQ‚É‚æ‚é‰ñ”ð‰Â”\‚ȉ@ŠOS’âŽ~—á‚ð‹K’è‚·‚éˆöŽq‚ÌŒŸ“¢D‘æ3‰ñ_“ÞìƒJƒ‹ƒWƒIƒƒWƒXƒgƒJƒ“ƒtƒ@ƒŒƒ“ƒXC‰¡•lC2000, 7. ´–ì’©”ŽCŒã“¡@‹œCˆä“c’q‘¥C‘¾Œ´@—mCŒÃ’J@—ºCX@ˆê”ŽC”~‘º@•qF’_”X‰Š‚É‘±”­‚µ‚½–å–¬ŒŒðǂ̈ê—áD‘æ260‰ñ“ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”—á‰ïC‰F“s‹{C2000, 7. –Ø‘ºˆê—YC¬›‰ë”üC“¡“cF”VC”~‘º@•qFS‹Ø[Çǂ̑ŠúŽófC‘ŠúŽ¡—ÂÌd—v«D‘æ20‰ñS‹Ø[ÇŒ¤‹†‰ïC “Œ‹žC2000, 7. ”~‘º@•qF‚ŒŒˆ³Ž¡—ÃEˆâ“`Žq‚©‚ç—Õ°‚Ü‚ÅD‘å㓌RASŒ¤‹†‰ïC‘åãC2000, 7 . ‰Y’†NŽqCŽsì—R‹I•vC–î–ì‘PŒÈC^“ç—²GCˆäŒ³´—²CŒË•”“¹—YCŽ›“c³ŽŸC‚—œ‹g‘¥CÎì—˜”VC“ìàVN‰îCZ“cWˆêCŽO•–¾•vC¬—ÑrˆêC“ú”ä@Œ‰C¼‰º_•½C‹vŽœ’¼ŒõC”~‘º@•qC’r‰º³•qFCryoablation‚É‚æ‚莡–ü‚¹‚µ‚ß‚½¶ŽºSë‹NŒ¹SŽº•p”‚Ì‚P—áD‘æ‚T‰ñ_“Þì—Õ°•s®–¬ƒtƒH[ƒ‰ƒ€C‰¡•lC2000, 7. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC´…@½C–{‹½—mˆê˜YCd­’©•FCŠâ‘ò—S“ñC¬—Ñ@òC’†ŒËì’m—ŠCÖ“¡r•FC‰Ô“cWˆêC‰œ“c@ƒC™ŽR@vC”~‘º@•qF‹}«S‹Ø[Ç‚Ìabortionii“W–hŽ~j‚©‚猩‚½‘ŠúŽófC‘ŠúŽ¡—ÂÌd—v«D‘æ20‰ñS‹Ø[ÇŒ¤‹†‰ïC“Œ‹žC2000, 7. ¬›‰ë”üF“Á•Êu‰‰@‹}«S‹Ø[ÇÇGS“d}‚łǂ±‚܂ŕª‚©‚é‚©D‘æ41‰ñ_“ÞìzŠÂŠíu‰‰‰ïC‰¡•lC2000, 7. ‰–”V“ü—mF‡•¹Ç‚𔺂¤‚ŒŒˆ³‚ÌŽ¡—ÃD’uŽ’ˆã‰ïC•Ä‘òC2000, 7. “c‘ºŒ÷ˆêCí“cN•vCŒË’J‹`”VC”~‘º@•qC–x“೎kC Dzau VJFƒŒƒjƒ“ˆâ“`Žq”­Œ»’²ß‹@˜‚ÌV‚½‚È“WŠJFŠjƒŒƒZƒvƒ^[LXR‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ‚W‰ñ“ú–{S‘Ÿà’c¥ƒtƒ@ƒCƒU[u‚ŒŒˆ³‚ÆŒŒŠÇ‘ãŽÓvŒ¤‹†•¬Œ¤‹†”­•\‰ïC“Œ‹žC2000, 7. “c‘ºŒ÷ˆêCàF’J@Œ¤C’ߌ©—SŽqCí“cN•vC–x“೎kC”~‘º@•qCDzau VJFcAMPî•ñ“`’BŒn‚É‚æ‚郌ƒjƒ“ˆâ“`Žq”­Œ»’²ß‚É‚¨‚¯‚éŠjƒŒƒZƒvƒ^[LXR‚Ì–ðŠ„‚É‚Â‚¢‚Ă̌Ÿ“¢D‘æ‚T‰ñzŠÂ’²ßˆöŽqŒ¤‹†‰ïC“Œ‹žC2000, 9. Îì—˜”VCZ“cWˆêC‹e’r”ü–çŽqC’†ì@‹BC¼‰º_•½C‘å“í‘×¶C¬—Ñ@òC¬›‰ë”üCž\‹v•ÛCC–Ø‘ºˆê—YC”~‘º@•qF“´•s‘SÇŒóŒQ‚¨‚æ‚ÑS–[‘e“®‡•¹—á‚É‚¨‚¯‚éA‚Žü”gƒJƒe[ƒeƒ‹ÄŽÜp‚ƃy[ƒXƒ[ƒJ[Až‚Ýp‚Ì“¯ŽžŽ{sD“ú–{lH‘ŸŠíŠw‰ïCŽl“úŽsC2000, 9. Îì—˜”VCZ“cWˆêC‹e’r”ü–çŽqC¬—Ñ@òC’†ì@‹BC¼‰º_•½C‘å“í‘×¶C¬›‰ë”üC‹vŽœ’¼ŒõC–Ø‘ºˆê—YC”~‘º@•qFS–[‘e“®‚ɑ΂·‚邎ü”gƒJƒe[ƒeƒ‹ÄŽÜp‚ƃy[ƒXƒ[ƒJ[Až‚Ýp‚ÌŒŸ“¢D‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïC‘åãC2000, 9. Îì—˜”VCZ“cWˆêC‹e’r”ü–çŽqC¬—Ñ@òC’†ì@‹BC¼‰º_•½C‘å“í‘×¶C¬›‰ë”üC‹vŽœ’¼ŒõC–Ø‘ºˆê—YC”~‘º@•qFDisopyramideÃ’Œã‚É“´Œ‹ß‰ñ•œŽžŠÔ‚ª‰„’·‚µ‚½“´•s‘SÇŒóŒQ‚Ì’·ŠúŒo‰ß‚ÌŒŸ“¢D‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïC‘åãC2000, 9. ˆä“c’q‘¥CŒã“¡@‹œC´–ì’©”ŽC‘¾Œ´@—mCŒÃ’J@—ºCX@ˆê”ŽC”~‘º@•qFŒ´ˆö•s–¾‚Ì• …‚Å”­Ç‚µ‚½Œ‹Šj«• –Œ‰ŠC‹¹–Œ‰Š‚Ì‚P—áD‘æ261‰ñ“ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”—á‰ïC“Œ‹žC2000, 9. ìè“TŽqC‚‹´‰„˜aC‹vŽœ’¼ŒõC–Ø‘ºˆê—YCÎì—˜”VC‹`ˆä@÷C“à–ì˜aŒ°C–¾ŠÔ‹ÎŽqC”~‘º@•qF’‹Œ«S‹Ø[ÇÇ—á‚ÌŒŒ’†BNP‚ÍS‹Ø[Ǘ̈您‚æ‚ÑLung Uptake‚ÅŽ¦‚³‚ê‚é‰^“®•‰‰×—U”­«‚Ì¶Žº‹@”\áŠQ‚𔽉f‚·‚éD‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïC‘åãC2000, 9. Š¿“߉ë•FCŒã“¡—tˆêC÷–Ø@ŒåC”nê@Œ’C‚–ØCˆêC‘ŠŒ´’¼•FCˆÀ‘º—Ç’jC‚–Ø@—mF–«”xŒŒðÇðÇpŒãÇ—á‚É‚¨‚¯‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÌŒø‰ÊD‘æ6‰ñS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïC‘O‹´C2000, 9. ‹e’r”ü–çŽqC‰H’¹@—TCÎì—˜”VFŒÇ—§«S–[ד®—á‚É‚¨‚¯‚é”wŒiˆöŽq‚ÌŒŸ“¢D‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïC‘åãC2000, 9. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC´…@½CÖ“¡r•FC‰œ“c@ƒC’†ŒËì’m—ŠC‰Ô“cWˆêC‰Ž“n@—ÍCž\‹v•ÛCC”~‘º@•qF‹}«L”Í‘O•Ç[ÇÄ‘a’Ê—á‚É‚¨‚¯‚é‹}«ŠúaVR—U“±‚ÌST•ΈʂÆ[ǃTƒCƒY‚Ƃ̊֌WD‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïC‘åãC2000, 9. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC–{‹½—mˆê˜YCd­’©•FCŠâ‘ò—S“ñC‰œ“c@ƒC‰Ô“cWˆêC‹{“‡‰hŽ¡Cž\‹v•ÛCC”~‘º@•qF‹}«S‹Ø[Ç‚Ìabortionii“W–hŽ~j‚ð–Ú“I‚Æ‚µ‚½Ä‘a’ʗÖ@‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïC‘åãC2000, 9. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC´…@½CÖ“¡r•FC‰œ“c@ƒC’†ŒËì’m—ŠC‰Ô“cWˆêC–{‹½—mˆê˜YCž\‹v•ÛCC”~‘º@•qFS‹Ø[Ç”­Ç‘Šú‚ÌC”½‰ž«’`”’‚Ì㸂ÆS‹Ø•ÛŒìì—p‚ÌŠÖ˜AD‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïC‘åãC2000, 9. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍCd­’©•FCŠâ‘ò—S“ñC¬—Ñ@òC‹{“‡‰hŽ¡Cž\‹v•ÛCC”~‘º@•qF‹}«‰º•Ç[Ç”­Ç‘Šú‚É‚¨‚¯‚銮‘S–[ŽºƒuƒƒbƒN‡•¹Žž‚ÌS–[ƒŒ[ƒg‚Ì—Õ°“IˆÓ‹`D‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïC‘åãC2000, 9. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC–{‹½—mˆê˜YCd­’©•FCŠâ‘ò—S“ñC¬—Ñ@òC´…@½Cž\‹v•ÛCC”~‘º@•qF[Ç‘O‹·SÇ—ð‚©‚ç‚Ý‚½‹}«S‹Ø[Ç”­ÇŽž‚̉ŠÇ‚ÌŠˆ“®«‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïC‘åãC2000, 9. Ä“¡r•FC–Ø‘ºˆê—YC¬›‰ë”üCÎì—˜”VC‰Ž“n@—ÍC–{‹½—mˆê˜YCŠâ‘ò—S“ñCd­’©•FC‹{‘ò‰hŽ¡C“È‹v•ÛCC”~‘º@•qF‹}«S‹Ø[ÇÄ‘a’Ê—á‚É‚¨‚¯‚éIschemic Preconditioning‚Ì[ǃTƒCƒYk¬Œø‰Ê‚ÉŠÖ‚·‚錟“¢D‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïC‘åãC2000, 9. Ä“¡r•FC–Ø‘ºˆê—YC¬›‰ë”üCÎì—˜”VC‰Ž“n@—ÍC–{‹½—mˆê˜YCŠâ‘ò—S“ñCd­’©•FC‹{‘ò‰hŽ¡C“È‹v•ÛCC”~‘º@•qF[Ç‘O‹·SÇ‚ÌIschemic Preconditioning‚Ìtime window‚ÆS‹Ø[ǃTƒCƒY‚Ƃ̊֘A«‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ48‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïC‘åãC2000, 9. ‰–”V“ü—mF‚ŒŒˆ³Ž¡—ÂÌV‚µ‚¢í—ªD‘啪ˆã‰È‘åŠwŒöŠJu‰‰‰ïC‘啪C2000, 9. ’ߌ©—TŽqCa’J@Œ¤C“c‘ºŒ÷ˆêCí“cN•vFHD—Ö@‚ðs‚Á‚½PDгŽÒ‚TÇ—á‚ÌŒŸ“¢D‘æ‚U‰ñ“ú–{• –Œ“§ÍŒ¤‹†‰ïC“¿“‡C2000, 9. ŒË“cŒ›FCÎì—˜”VC–ì‘ò’¼Ž÷C—އ‹v•vC¬—Ñ@òC–Ø‘ºˆê—YC”~‘º@•qFDDDƒy[ƒXƒ[ƒJ[‚É‚¨‚¯‚鎊“K–[ŽºŽžŠÔ‚ÌTEI INDEX‹y‚ÑS–[—˜”Aƒzƒ‹ƒ‚ƒ“‚É‚æ‚é”äŠrŒŸ“¢D“ú–{S‘Ÿ•aŠw‰ïC‘åãC2000, 9. ”‹´‘åŽ÷CŠâŸº˜a–çC¬–ì]˜a‘¥F‹}«GVHD‰ñ•œŒã‚Ìœ‘ƒLƒƒ‰ƒ}ƒEƒX‚É‚¨‚¯‚éT×–EƒŒƒp[ƒgƒŠ[Œ`¬‚Æ‹@”\‚̉ðÍD‘æ‚S‰ñ–kŠC“¹–Ɖu’k˜b‰ïCŽD–yC2000, 9. ˜a“c@“ÄCA“c^ˆê˜YC”~‘º@•qFACE‘jŠQ–ò‚¨‚æ‚уJƒ‹ƒVƒEƒ€hR–ò‚̃qƒg‘O˜r’ïRŒŒŠÇ“à”ç‹@”\‚ւ̉e‹¿D‘æ21‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïCŽD–yC2000, 9. ’ߌ©—TŽqCa’J@Œ¤C“c‘ºŒ÷ˆêCí“cN•vC‰Í–ì•q˜YCš L—C¬—Ñr‰îD’_`«• –Œ‰Š‚𕹔­‚µ‚½ŒŒ‰t“§ÍгŽÒ‚Ì‚P—áD‘æ65‰ñ_“Þ쌧“à‰ÈˆãŠw‰ïW’k‰ïCŒú–Ø2000, 10. ’·’JìŽqCˆÀ“c@Œ³C‹vŽœ’‰ŽiCŽu‘º@ŠxC”~‘º@•qFŒŒ‰t“§ÍгŽÒ‚ÌŒŒˆ³“ú“à•Ï“®D‘æ‚P‰ñ‰¡•lÓ쓧̓Zƒ~ƒi[C‰¡•lC2000, 10. •H–Ø@’qCŽu˜a’‰ŽuC‰¡ŽR’mŽqC–q—R”üŽqC–쑺³ªCŒã“¡@‹œC”~‘º@•qF‘å’°“àŽ‹‹¾ŒŸ¸ŠŒ©‚©‚ç‚Ý‚½‘å’°ŠàŒŸf‚Ì—L—p«‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ38‰ñ“ú–{Á‰»ŠíW’cŒŸfŒŸfŠw‰ïH‹G‘å‰ïC‹ž“sC2000, 10. ¼‰º_•½CZ“cWˆêCÎì—˜”VC‘å“í‘×¶C“ìàVN‰îC‹vŽœ’¼ŒõC–Ø‘ºˆê—YC”~‘º@•qF‰‰ñ“d‹C“Iœ×“®–³Œø‚Å‚ ‚Á‚½–«S–[ד®‚ɑ΂µamiodar one“à•ž“Š—^Œã“d‹C“Iœ×“®‚ɬŒ÷‚µ‚½Ç—áD‘æ17‰ñ“ú–{S“dŠw‰ïC“Œ‹žC2000, 10. –q—R”üŽqCŽu˜a’‰ŽuC•H–Ø@’qC‰¡ŽR’mŽqC–쑺³ªFEˆæˆÝWŒŸŠÔÚ‘¢‰e–@‚É‚¨‚¯‚é‚”Z“xƒoƒŠƒEƒ€–@‚Ì—L—p«‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ38‰ñ“ú–{Á‰»ŠíW’cŒŸfŠw‰ïH‹G‘å‰ïC_ŒËC2000, 10. —WŽR”ü“ÞŽqC–î–ì‰plC²X–Ø—´CX“c—L‹IŽqCàV“c—æ–¯C‰Pˆä@FCŠâˆä–FOC’†‘ºŒõÆDP‹v“Iƒy[ƒXƒ[ƒJ[A‚¦ž‚ÝŒã‚É”­Ç‚µ‚½MRSA‚É‚æ‚é‰ESŒnŠ´õ«S“à–Œ‰Š‚Ì‚P—áD‘æ65‰ñ_“Þ쌧“à‰ÈˆãŠw‰ïW’k‰ïCŒú–ØC2000, 10. A“c^ˆê˜YC“Œ@KmC”~‘º@•qFL-arginine‚ÍNO‚ð‰î‚µ‚ăAƒ“ƒWƒIƒeƒ“ƒVƒ“õÀ‚ÌŒŒŠÇŽûkì—p‚ðŒ¸Žã‚³‚¹‚éD‘æ23‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ïC•Ÿ‰ªC2000, 10. •½˜aLmC㌴—_Žu•vC’†“‡@_C— o—Ç”ŽC”~‘º@•qFƒŠƒ|ƒJƒCƒ“Œ^ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“D‡¬y‘f‚Ì“®‘ԂƈӋ`D‘æ23‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ïC•Ÿ‰ªC2000, 10. X@—TsC‰“ŽRœÄˆêC•Ÿˆä˜aŽ÷C‰º’ÇŽqC‰iŽ@ŒMC’†”ö³sC’|‘ºmŽuC’†ì@[F¶–[Œ´”­‚̈««Žîᎂ̂P—áD‘æ178‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïC“Œ‹žC2000, 12. X“c—L‹IŽqC‰Pˆä@FC”ªŒLG”VC•P–ìG˜NCàV“c—æ–¯C²X–Ø—´C—WŽR”ü“ÞŽqC–î–ì‰plC”–Ø­LF‘ÒŠú“IŠ¥“®–¬ƒXƒeƒ“ƒg—¯’upŒã‚ÌÄ‹·ó‚ÆŒŒ’†Lpiaj”Z“x‚ÉŠÖ‚·‚錟“¢F‘æ‚Q‰ñHeart riskŒ¤‹†‰ïC‰¡•lC2000, 10. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC¬—Ñ@òCž\‹v•ÛCC”~‘º@•qF¶‘O‰ºsŽ}‹ßˆÊ•”•Âǂ̋}«‘O•Ç[ǂɂ¨‚¯‚éaVR—U“±‚ÌST•Έʂ̗հ“IˆÓ‹`D‘æ17‰ñ“ú–{S“dŠw‰ïŠwpW‰ïC“Œ‹žC2000, 10. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC–{‹½—mˆê˜YCd­’©•FCŠâ‘ò—S“ñC‰œ“c@ƒC“È‹v•ÛCC”~‘º@•qF‹}«‰º•Ç[Ç”­Ç‘Šú‚ÌŠ®‘S–[ŽºƒuƒƒbƒN‡•¹—á‚ɑ΂·‚鑊úÄ‘a’ʂ̗L—p«D‘æ14‰ñ“ú–{Х޾гŠw‰ïCL“‡C2000, 10. Šâ’ØkôC‰¶“c@Œ’C“©@@—zC“¡“cF”VCŒË’J‹`KC”~‘º@•qCÎì‹`OFWHOLE CELL BINDING ASSAY–@‚ð—p‚¢‚½b 1ƒAƒhƒŒƒiƒŠƒ“Žó—e‘̂ɂ¨‚¯‚éSEQUESTRATION‚ÌŒŸ“¢D‘æ22‰ñƒJƒeƒR[ƒ‹ƒAƒ~ƒ“‚ÆzŠÂŠíŒnŒ¤‹†‰ïC“Œ‹žC2000, 10. ”~‘º@•qFACE‘jŠQ–ò‚Í•K—v‚Å‚ ‚éD‘æ‚U‰ñDILEMMA IN CLINICAL CARDIOLOGYŒ¤‹†‰ïCVhC2000, 10. Œã“¡@‹œCˆä“c’q‘¥C´–ì’©”ŽC^“‡—YˆêC‘¾Œ´@—mCŒÃ’J@—ºCX@ˆê”ŽCˆéŠL@ƒCŽRè‰x•vC•H–Ø@’qC‰¡ŽR’mŽqCŽu˜a’‰ŽuC”~‘º@•qFŠÌ×–EŠà‚É‚½‚¢‚·‚éPEITŒã‚ÌŽ¡—ÃŒø‰Ê”»’è‚É‚¨‚¯‚éUS-angiography‚Ædynamic-MRI‚Ì”äŠrD‘æ‚S‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ïC_ŒËC2000, 10. ¬—Ñ@òCŽO’J—E—YC–Ø‘ºˆê—YC‰Ž“n@—ÍC–{‹½—mˆê˜YCŠâàV—S“ñCd­’©•FC¬›‰ë”üC’†ì@‹BC’†ŒËì’m—ŠCÄ“¡r•FC‰œ“c@ƒC‰Ô“cWˆêC”~‘º@•qFŠjˆãŠw“IŒŸ¸‚ɂČo‰ßŠÏŽ@‚µ“¾‚½‚½‚±‚‚ڌ^S‹ØÇ‚Ì‚P—áD‘æ‚V‰ñ_“ÞìSPECTŒ¤‹†‰ïD‰¡•lC2000, 10. Žu˜a’‰ŽuC•H–Ø@’qC–q—R”üŽqC‰¡ŽR’mŽqC–쑺³ªCŒã“¡@‹œCŽç’Jº•FCì–¼ˆê˜NC”~‘º@•qFHelicobacter@pyloriœ‹ÛŽ¡—ÃŽž‚É‚¨‚¯‚鑽ܑϫ“ûŽ_‹Û»Ü•¹—p‚Ì—L—p«‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ42‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ïC_ŒË2000, 10. “cŒ´—Ç—YC‚‘º@•CŠC˜V–¼r–¾CΈäác’jC’†’J@•qCœA‰ªŒcŽ¡C‰Ô’J²‹vCˆÀ‘º—Ç’jC’†’J@•qCŽRŠÝ³˜aC‹{•–M•vFŒo‹¹•ÇSƒGƒR[–@‚Ì‘m–X•Ùˆí’E•”ˆÊf’f”\G‚“x‘m–X•Ù‹t—¬—á‚É‚¨‚¯‚ép’†ŠŒ©‚Ƃ̑ΔäD ‘æ177‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïC“Œ‹žC2000, 10. “c‘ºŒ÷ˆêC–x“೎kCàF’J@Œ¤C’ߌ©—SŽqCí“cN•vCDzau VJC”~‘º@•qFƒŒƒjƒ“ˆâ“`Žq“]ŽÊ’²ßˆöŽq‚Ì’P—£‚Æ‚»‚Ì‹@”\‰ðÍFcAMP‚É‚æ‚é”­Œ»§Œä‚É‚¨‚¯‚éV‚µ‚¢ƒƒJƒjƒYƒ€‚Ì’ñ¥D‘æ23‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ïC•Ÿ‰ªC2000, 10. “c‘ºŒ÷ˆêFƒŒƒjƒ“ˆâ“`Žq“]ŽÊ’²ßˆöŽq‚Ì’P—£‚Æ‹@”\‰ðÍD“¡‘òŽs–¯•a‰@‘æ70‰ñ“à‰È‘ÌŒ±ŠwKW’k‰ïC“¡‘òC 2000, 10. “c‘ºŒ÷ˆêC’ߌ©—SŽqCàF’J@Œ¤Cí“cN•vC”~‘º@•qFŽüŠú“IL“WŽhŒƒ‚É‚æ‚錌ŠÇ•½ŠŠ‹Ø×–EƒtƒBƒuƒƒlƒNƒ`ƒ“ˆâ“`Žq”­Œ»Šˆ«‰»‚ɑ΂·‚éAT1Žó—e‘ÌhR–òiƒJƒ“ƒ_ƒTƒ‹ƒ^ƒ“j‚ÌŒø‰Ê‚ɂ‚¢‚ÄD‘æ‚T‰ñ•“c‚ŒŒˆ³ƒVƒ“ƒ|ƒWƒEƒ€C‰«“êC2000, 11. “c‘ºŒ÷ˆêCí“cN•vCa’J@Œ¤C’ߌ©—SŽqC–x“೎kC”~‘º@•qCDzau VJFŠjƒŒƒZƒvƒ^[‚É‚æ‚郌ƒjƒ“ˆâ“`Žq”­Œ»’²ß‚ɂ‚¢‚ÄFcAMP‚É‚æ‚郌ƒjƒ““]ŽÊ§ŒäƒƒJƒjƒYƒ€‚ÌV‚½‚È“WŠJDŽáŽèŒ¤‹†§—ãÜŽóÜu‰‰D‘æ4‰ñ“ú–{SŒŒŠÇ“à•ª”å‘ãŽÓŠw‰ïC‘åãC2000, 11. “c‘ºŒ÷ˆêFt•s‘SгŽÒ‚Ìœ•a•ςɂ‚¢‚ÄD“¡‘òŽs–¯•a‰@•½¬12”N“x‘æ1‰ñt‘Ÿ•auÀC“¡‘òC2000, 11. _‹{_”VC‚–ØM‰ÃC‰Ÿì@mC‹´–{’B•vCŠC˜V–¼r–¾C’|‰ºN‘ãC–ØŒ´@ŽÀC–î‰Ô^’mŽqCŒË’J‹`KC”~‘º@•qF–«tá±t‰Š‘ˆ«‚É”º‚¤‹}«t•s‘S¶‚¶‚½nutcrackerŒ»Û‡•¹IgAtǂ̂P—áD‘æ30‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ïC“Œ‹žC2000, 11. àV“c—æ–¯C‰Pˆä@FC”ªŒLG”VCX“c—L‹IŽqC²X–Ø—´C—WŽR”ü“ÞŽqC–î–ì‰plF‘ŠúÄŠÁ—¬‚RŽžŠÔŒãCS”j—ô‚ð”F‚ß‚½Ç—áD‘æ47‰ñ_“ÞìPTCAŒ¤‹†‰ïŠwpW‰ïC‰¡•lC2000, 11. ¬ˆäŽè—TˆêCŽO’J—E—YC”~‘º@•qC‚‹´‰„˜aC¼Œ´@¡C‹g쎑¥FEmory Cardiac Tool‚ð—p‚¢‚½S“d“¯ŠúSPECTS‹@”\‰ð͂̌Ÿ“¢D‘æ40‰ñ“ú–{ŠjˆãŠw‘‰ïC_ŒËC2000, 11 . ‰–”V“ü—mF‚ŒŒˆ³‚̘bDŠ™‘q’†‰›ƒ[ƒ^ƒŠ[ƒNƒ‰ƒuu‰‰‰ïCŠ™‘qC2000, 11. ‚‹´KŽqC‚–ØM‰ÃCŠâ’ØkôC‹´–{’B•vC¬–ìG“ñC‰Ÿì@mC“y‹´–õŽuC•½˜aLmC’|‰ºN‘ãC–ØŒ´@ŽÀC–î‰Ô^’mŽqCŒË’J‹`KC”~‘º@•qFŒŒ‰t“§Í“±“üŽž‚ɓ«–«œ‘‰Š‚ð‡•¹‚µ‚½‚P—áD‘æ16‰ñ_“Þ쌧“§ÍŽ{ݘA—‹¦‹c‰ïE‘æ60‰ñ_“ÞìtŒ¤‹†‰ï‡“¯Œ¤‹†‰ïC‰¡•lC2000, 11. ‘ê‘ò—˜ˆêFŋ߂Ì~ˆ³Ž¡—Âɂ‚¢‚ÄD¬“cŒ´Žs–òÜŽt‰ïC¬“cŒ´C2000, 11. ”‹´‘åŽ÷CŠâŸº˜a–çC¬–ì]˜a‘¥FƒAƒœ‘ˆÚAŒã‚ÌT×–EƒŒƒp[ƒgƒŠ[Œ`¬‚Æ‹@”\‚É‹y‚Ú‚·‹}«GVHD‚̉e‹¿D‘æ30‰ñ“ú–{–ƉuŠw‰ï‘‰ïCå‘äC2000, 11. –î‰Ô^’mŽqCŒË’J‹`KC–ØŒ´@ŽÀC•½˜aLmC‚–ØM‰ÃC‘å¼r³C”~‘º@•qF“¯Žíœ‘ˆÚAŒã’`”’”A‚ªoŒ»‚µ‚½3Ç—áD‘æ30‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ïC“Œ‹žC2000, 11. X“c—L‹IŽqC‰Pˆä@FC”ªŒLG”VCàV“c—æ–¯C²X–Ø—´C—WŽR”ü“ÞŽqC–î–ì‰plC”–Ø­LF‘m–X•Ù‹·óǂ𔺂í‚È‚¢¶–[“à‹‘åŒŒð‚Ì‚P—áD“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ178‰ñŠwpW‰ïC“Œ‹žC2000, 12. –î–ì‰plCX“c—L‹IŽqC‰Pˆä@FC”ªŒLG”VCàV“c—æ–¯C²X–Ø—´C—WŽR”ü“ÞŽqC”–Ø­LF‘m–X•Ù‹·óǂ𔺂í‚È‚¢¶–[“à‹‘åŒŒð‚̈ê—áD“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ178‰ñŠwpW‰ïC“Œ‹žC2000, 12. –Ø‘ºˆê—YF‹}«S‹Ø[Çǂ̑Šúf’f‚Æ‘ŠúŽ¡—ÂÌd—v«D“ú–{ˆãŽt‰ï¶ŠU‹³ˆçuÀC”ŸŠÙC2000, 12. –Ø‘ºˆê—YF’´^‹}«S‹Ø[ÇŽ¡—Âɂ¨‚¯‚éŋ߂Ìi•àD‘æ42‰ñ_“ÞìzŠÂŠíu‰‰‰ïC‰¡•lC2000, 12. ¬›‰ë”üC–Ø‘ºˆê—YCÎì—˜”VC‰Ž“n@—ÍC–{‹½—mˆê˜YCd­’©•FCŠâ‘ò—S“ñCž\‹v•ÛCC”~‘º@•qF‹}«‰º•Ç[Ç”­Ç‘Šú‚ÌŠ®‘S–[ŽºƒuƒƒbƒN‡•¹—á‚ɑ΂·‚鑊úÄ‘a’ʂ̗L—p«D‘æ14‰ñ“ú–{Х޾гŠw‰ïŠwpW‰ïCL“‡C2000, 12. Œã“¡@‹œCˆä“c’q‘¥C´–ì’©”ŽC‘¾Œ´@—mCŒÃ’J@—ºCX@ˆê”ŽC”~‘º@•qF’´‚—îŽÒi90Îj‚ÌŠÌ×–EŠà‚ÌŽ¡—ÃŒoŒ±D ‘æ262‰ñ“ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”—á‰ïC“Œ‹žC2000, 12. 1998”N•âˆâ ”~‘º@•qC“c‘ºŒ÷ˆêFSŒŒŠÇŒn‘gDE×–E‚É‚¨‚¯‚éRAŒn‚¨‚æ‚Ñ×–EŠOŠîŽ¿ˆâ“`Žq‚Ì”­Œ»’²ß‚ÆAT1Žó—e‘̖̂ðŠ„D‘æ‚R‰ñ•“c‚ŒŒˆ³ƒVƒ“ƒ|ƒWƒEƒ€i‘åãjC1998, 11D 1999”N•âˆâ Š¿“߉ë•FCŠp“c@“™C‹{èrˆêCŒã“¡—tˆêC‘å•@“NCXˆä@Œ÷CˆÀ“c@‘C”nê@Œ’C–ìX–ØGF‹}«S‹Ø[Çǂ̗\Œã•]‰¿‚É‚¨‚¯‚éƒgƒƒ|ƒjƒ“T‚Ì—L—p«D‘æ63‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïC“Œ‹žC1999, 3. ‘ê‘ò—˜ˆêC“c‘º_ŽOCŒ´@–F‹IC“¡–{Œ’‹gC¼‰YŒªˆêF–«ˆÛŽ“§ÍгŽÒ‚Ì•nŒŒ‚ÆÔŒŒ‹…ƒTƒCƒY•ª•z•iRDWj‚Ƃ̊֌WD‘æ44‰ñ“ú–{“§ÍˆãŠw‰ï‘‰ïC‰¡•lC1999, 6. ‘ê‘ò—˜ˆêFt‘Ÿ•a‚Ì—\–h‚ÆŽ¡—Ã@_“Þ쌧CŠJ¬’¬C1999, 11. “c‘º_ŽOC‘ê‘ò—˜ˆêCr–ØrsFtáŠQŽž‚ÌPTH rpD‘æ44‰ñ“ú–{“§ÍˆãŠw‰ï‘‰ïC‰¡•lC1999, 6.
iŒ¤‹†•¬‹àj A“c^ˆê˜Yi‘ãjFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“i1-7j‚̃qƒg‚É‚¨‚¯‚錌ŠÇì—p‚ÆSŒŒŠÇ•aŽ¡—Âւ̊֗^D•¶•”ȉȊwŒ¤‹†”ï•â•‹àˆê”ÊŒ¤‹†Ci11670697j100–œ‰~D “à–ì˜aŒ°i•ª’SjFŒú¶ÈzŠÂŠí•aŒ¤‹†ˆÏ‘õ”ï12Žw|‚PS‹Ø•s‘S‚ɑ΂·‚éS‹Ø•ÛŒì—Ö@‚Ì—Õ°‰ž—p‚ÉŠÖ‚·‚鑽Ž{Ý‹¤“¯Œ¤‹†C110–œ‰~D “c‘ºŒ÷ˆêF“ú–{ŠwpU‹»‰ïŠCŠO“Á•ÊŒ¤‹†ˆõDƒŒƒjƒ“-ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn‚Ì•a‘Ô¶—Šw“IˆÓ‹`‚ÉŠÖ‚·‚镪Žq¶•¨Šw“IŒ¤‹†C1998-2001C520–œ‰~D Dzau VJ, Tamura K, Anderson LM, McEwan P, Pratt RE: NIH R37-HL35610. Renin gene expression in cardiovascular regulation. 2000, $189,000D “c‘ºŒ÷ˆêF‘æ‚W‰ñ“ú–{S‘Ÿà’cEƒtƒ@ƒCƒU[u‚ŒŒˆ³‚ÆŒŒŠÇ‘ãŽÓvŒ¤‹†•¬‹àDƒŒƒjƒ“ˆâ“`Žq”­Œ»’²ß‹@˜‚ÌV‚½‚È“WŠJFŠjƒŒƒZƒvƒ^[LXR‚ÌŠÖ—^‚ɂ‚¢‚ÄD2000, 10–œ‰~D “c‘ºŒ÷ˆêF‘æ‚T‰ñzŠÂ’²ßˆöŽqŒ¤‹†‰ïŒ¤‹†•¬‹àDcAMPî•ñ“`’BŒn‚É‚æ‚郌ƒjƒ“ˆâ“`Žq”­Œ»’²ß‚É‚¨‚¯‚éŠjƒŒƒZƒvƒ^[LXR‚Ì–ðŠ„‚É‚Â‚¢‚Ă̌Ÿ“¢D2000, 30–œ‰~D “c‘ºŒ÷ˆêF‘æ‚S‰ñ“ú–{SŒŒŠÇ“à•ª”å‘ãŽÓŠw‰ïŽáŽèŒ¤‹†§—ãÜDŠjƒŒƒZƒvƒ^[‚É‚æ‚郌ƒjƒ“ˆâ“`Žq”­Œ»’²ß‚ɂ‚¢‚ÄFcAMP‚É‚æ‚郌ƒjƒ““]ŽÊ§ŒäƒƒJƒjƒYƒ€‚ÌV‚½‚È“WŠJD2000, 10–œ‰~D “ú”ä@Œ‰F㌴‹L”O¶–½‰ÈŠwà’cŠCŠO—¯Šw•¬‹àiƒ|ƒXƒgƒhƒNƒgƒ‰ƒ‹ƒtƒFƒ[ƒVƒbƒvjDŒŒŠÇ“àƒGƒR[‚É‚æ‚é—Õ°Œ¤‹†‚¨‚æ‚ÑV‹@޲ŠJ”­D •½˜aLmF‰ÈŠwŒ¤‹†”ï•╋ৗ㌤‹†”ïAD‘gDƒJƒŠƒNƒŒƒCƒ“ˆâ“`Žq‘½Œ^‚Æ–{‘Ô«‚ŒŒˆ³C150–œ‰~C2000D